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The single nucleotide polymorphism (SNP) at codon 72 of the tumor 
suppressor gene p53 codes for either an arginine (R) or proline (P) (p53 R72P). 
This SNP may impact how cells respond to genotoxic insult. Studies in cell 
culture and in tissues from mouse models of the SNP indicate that, in response 
to gentoxic treatment, the two variants may differentially induce apoptosis and 
expression of p53 target genes. In epidemiological studies, the P variant is 
associated with decreased cancer survival and increased risk of side-effects from 
genotoxic cancer treatment. Genotoxic therapy is still the mainstay of cancer 
treatment, and doxorubicin and/or ionizing radiation (IR) are used in many 
treatment regimens. In this project I employed our mouse models of the p53 
R72P polymorphism to test how this SNP modulates physiological effects of 
doxorubicin and IR. To test how the p53 R72P polymorphism affects doxorubicin 
tolerance at a physiological level and in gene expression profiles, I performed 
blood counts and RNA sequencing of tissues from doxorubicin treated and 
untreated p53 R72P mice. To test how the p53 R72P polymorphism affects IR 
tolerance, I performed a survival study, immunohistochemical (IHC) staining, 
blood counts and used quantitative PCR to analyze p53 target gene expression 
in IR treated and untreated p53 R72P mice. In both studies I stringently 
controlled for background strain, age and sex. Due to an unexpected tolerance 
to doxorubicin in the FVB mouse strain employed, the doxorubicin studies were 
inconclusive. While IR did elicit a significant response, my findings did not 
support a role for the p53 R72P polymorphism in modulating the adverse effect 
IR therapy, and indicate that personalization of these therapies based on this 
SNP could have limited clinical utility.  
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Chapter 1: 
Background and Introduction 
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1.1 The p53 tumor suppressor protein 
 
1.1.1 Discovery of the p53 protein and its major functions  
 
In 1979, four laboratories, all of which were screening transformed cell 
lines for potential tumor antigen candidates, independently published findings 
regarding an approximately 53kD protein. Three reports showed the protein 
could be detected by immunoprecipitation with anti-simian-virus 40 (SV40) 
tumor serum in SV40-transformed mouse, hamster, rat, monkey or human 
cultures or in uninfected embryonic carcinoma lines1-3. A fourth report 
demonstrated this protein (sensibly baptized “p53”) could also be 
immunoprecipitated by antisera produced in mice immunized against sarcomas 
in both murine sarcoma tissues and transformed murine cell lines, but not in 
primary mouse tissues or cultures 4. Since p53 did not share features of viral 
proteins, these reports hypothesized that p53 was a cellular protein and was 
essential for and/or induced by cellular transformation/immortalization1-4. 
In accordance with these initial hypotheses, reports began to emerge 
showing that either p53 or very similar proteins were present in many human 
tumor cell lines. Other reports showed that some breast cancer patients had 
anti-p53 antibodies in their sera, and that colorectal and breast tumors had 
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detectable levels of p535-7. Early experiments, which showed an inhibition of 
DNA synthesis in serum stimulated 3T3 cell culture following micro-injection of 
anti-p53 antibodies, suggested that p53 was a positive regulator of growth8. In 
1984, three cell culture studies in Nature claimed that p53 expression in primary 
cells could induce immortality either independently or in co-operation with other 
tumorigenic genes9-11. Considering these data, it initially seemed reasonable to 
conclude that p53 was an oncogene. 
However, shortly thereafter, early p53 aficionados, such as Levine and 
Vogelstein, showed that vectors coding for wild-type (WT) p53 introduced in 
tumor cell cultures actually suppressed cell growth. Furthermore, they 
demonstrated that only mutated p53 allowed transformation of cell lines by 
oncogenes12-14. It was soon understood that mutated p53 co-operated with 
other oncogenes in a dominant negative fashion, and that a wide variety of 
neoplasia contained mutant p53 (reviewed in 15). Thus, p53 was not an 
oncogene, but an important tumor suppressor gene.  
Several groups then began to reveal the cellular mechanisms responsible 
for p53’s ability to suppress tumor growth. In 1991, Kastan et al. showed that 
p53 protein increased in response to DNA damaging agents, and this coincided 
with G1 growth arrest16. A few years later, p53’s growth suppressive abilities in 
the context of DNA damage were shown to be contingent, in part, on 
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transcriptional activation of proteins involved in cell cycle arrest, including cyclin- 
dependent-kinase-inhibitor-1A (Cdkn1a/p21)17,18 and growth-arrest-and-DNA 
damage-inducible-45-alpha (Gadd45a)19,20. Concurrent with the discovery of 
p53’s ability to induce growth arrest, other investigators were taking notice of 
p53’s ability to induce apoptosis 21,22. It was soon shown that p53 induces 
apoptosis by up-regulation of the pro-apoptotic gene BCL2-associated-X-
protein (Bax)23. Other pro-apoptotic genes induced by p53, including p53-
upregulated-modulator-of-apoptosis (Puma/Bbc3)24 and phorbol-12-myristate-
13-acetate-induced-protein-1 (PMAIP1/Noxa)25, were discovered later. 
Furthermore, studies showed that p53 can also induce apoptosis via 
protein/protein interactions with Bcl-2 family pro- and anti-apoptotic proteins at 
the mitochondrial membrane (reviewed in 26).  
Of course, the role of p53 as a transcription factor is not limited to the 
few genes listed above. In fact, a 2008 review found that WT p53 (but not 
mutant p53) either negatively or positively regulated the expression of 129 
genes through p53’s interaction with gene promoters. These 129 genes were 
those that met the stringent requirement of containing a response element for 
p53 and in which chromatin immunoprecipitation (ChIP) assays or gel shift assays 
showed p53 binding to promoter elements. Furthermore quantitative RNA 
analysis and protein level analysis had to show increased or decreased activity in 
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response to WT p5327. More recent high-throughput sequencing and analysis 
techniques, unsurprisingly, have shown even more p53 transcriptional targets. A 
2013 study used p53 WT and p53-/- mouse embryonic fibroblasts (MEFS) 
exposed to the genotoxic agent doxorubicin to assess p53 target genes by both 
ChIP sequencing and RNA sequencing. This study found 423 genes bound by 
p53 at their promoters and differently regulated in a p53 dependent manner. 
Gene ontology analysis showed that there was a significant up-regulation of 
genes involved in cell cycle arrest and apoptosis. These data confirm the 
importance of these long-identified pathways as being central to the response 
of p53 to genotoxic insult. Interestingly, they also found p53 binding to, and 
p53 dependent up-regulation of autophagy-related genes and down-regulation 
of genes involved in growth 28.  
That p53 may be involved in autophagy is not surprising. For 
approximately a decade p53 has been implicated in regulating metabolism. 
Transcriptional activation of AMP-activated-protein-kinase (AMPK) by p53 
suppresses mammalian-target-of rapamycin (mTOR) signaling. Such reduced m-
Tor pathway signaling decreases cell growth (protein synthesis) and increases 
autophagy, although whether these effects are tumor-suppressing or tumor-
promoting is subject to some debate (reviewed in 29). 
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 There are many other functions of p53 that could be important to cancer 
progression or cancer therapy research. For example, p53 transcriptional 
activation of p21 is involved in senescence as well as cell cycle regulation. Other 
potentially important roles include reactive oxygen species (ROS) regulation, 
regulation of angiogenesis, roles immunity and roles in DNA damage repair 
(reviewed in30). Exploring most of these functions in detail is beyond the scope 
of this dissertation, but the role of p53 in DNA repair should be mentioned.  
The involvement of p53 in DNA repair can occur both through its role as 
a transcription factor and through non-transcription-dependent interactions. In 
cell culture studies and in-vitro assays of most types of DNA repair, WT p53 
either increases or decreases efficiency when compared to the mutated p53 or 
p53 deficiency. In nucleotide excision repair (NER), p53 may transactivate genes 
involved in UV damage recognition as well as affect enzymatic activity of 
proteins involved in UV damage repair. In base excision repair (BER), WT p53 
protein seems to enhance activity of some BER-associated-endonucleases and –
DNA-polymerases and other BER associated enzymes, under certain conditions. 
Furthermore, p53 appears to associate, in vitro, with some of these enzymes. In 
mismatch repair (MMR), p53 transactivates the MSH2 gene, and colocalizes with 
MSH2 and other proteins involved in MMR (reviewed in 31). 
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The role of p53 in DNA double strand breaks (DSB) is especially 
important to this thesis, as DSB repair is important in both the treatment efficacy 
and side effects of cancer chemotherapy and ionizing radiation treatment. DNA 
DSBs can be repaired by the more error-prone non-homologous-end-joining 
(NHEJ), or by or homologous recombination repair (HRR), a reduced-error 
method of DNA repair that relies on the presence of an intact homologous sister 
chromatid. The role of p53 in NHEJ is not clear. Studies using plasmid assays 
have given conflicting results as to whether p53 inhibits or enhances NHEJ. In 
HRR, p53 appears to be inhibitory, as p53 deficient mice show increased 
frequency of HHR. The inhibitory effects on HHR appear to be transactivation-
independent. The binding of WT p53 to RAD51 is well established, and this 
binding may inhibit strand invasion and/or branch migration necessary for 
recombination. Furthermore, serine 15 (S15) phosphorylated p53 interacts with 
replication-protein-A (RPA) in earlier stages of HHR to suppress this method of 
repair (reviewed in31,32).  
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1.1.2 Regulation of p53 
 
The regulation of p53 has been the subject of intense investigation since 
its discovery. As early as 1984, Maltzman and Czyzyk showed that DNA 
damaging agents could induce increased levels of p53 which also coincided 
with cell cycle arrest 33. However, Kastan et al. showed in 1991 that this did not 
coincide with increased p53 mRNA production16, suggesting that regulation of 
protein levels was not by regulation of transcription. Further studies led to the 
current understanding of p53 regulation. Under normal cellular conditions, p53 
levels are kept in check by a feedback loop in which p53 itself promotes 
transcription of its own negative regulator, mouse-double-minute-2-homolog 
(Mdm2)34-37. Mdm2 is a ubiquitin ligase which interacts with and ubiquitinates 
p53, targeting p53 for subsequent proteasome degradation38-40. However, under 
genotoxic stress, the ataxia-telangiectasia-mutated (ATM) kinase phosphorylates 
p53 at serine 15 and inhibits p53/Mdm2 interactions and therefore, its 
ubiquitination and degradation41,42.  
The regulation of p53 is actually much more complex: several other post-
translational modifications and protein-protein interactions have been found to 
regulate p53 levels and activities in the Mdm2 pathway and myriad other 
pathways (reviewed in 43). It should also be noted that Wang et al. would show 
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that p53 mRNA does increase in response to some chemotherapeutic agents in 
cell culture, and that p53 itself is a transcription factor at least partially 
responsible for this increase44. The general consensus remains that the Mdm2 
pathway described above is the most important regulatory pathway for p53 
activity45,46. 
 
1.1.3 Functional domains of the p53 tumor suppresser protein  
 
The p53 protein has domains essential for most of its known functions. 
The transactivation domain, amino acid (AA) 1-60, is the site of phosphorylation 
events that stabilize p53 and prevent Mdm2 interaction under cellular stress and 
contains one of two regions essential for transactivation of target genes41,42,47. 
Much of p53’s transcriptional regulation is also contingent on the DNA binding 
domain of the protein AA 102-29248-50. Accordingly, many “hotspot” mutations 
of the p53 gene in cancer occur in these domains, and these mutations can 
either be loss-of-function mutations which inhibit normal p53 transcriptional 
function or gain-of-function changes in which aberrant p53 induces transcription 
that increases oncogenic signaling, probably through interaction with other 
transcription factors (reviewed in51,52). AA 311-363 comprises the tetramerization 
domain48,53. The C-terminal regulatory domain (AA 363-393) is the site of many 
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post-translational modifications; these include ubiquitination by Mdm2 that 
leads to p53’s degradation and other modifications that may affect transcription 
and interactions with DNA repair enzymes54-57. 
Walker and Levine first characterized the proline rich domain (AA 61-94) 
in 1996. They found it contained five repeats of the sequence proline-two-other-
amino-acids-proline (PxxP), and that elimination of this domain did not repress 
p53 mediated transcription (by reporter systems) or p53 stabilization. However, 
it did attenuate p53’s growth arrest capabilities. Because PxxP domains bind src 
homology 3 (SH3) domains of other proteins and this binding activity is 
important in signal transduction pathways58,59, they hypothesized that p53’s PxxP 
domain may be essential for at least some downstream signaling60. Another 
group did not find that elimination of the PxxP domain of the p53 gene 
decreased growth arrest by p53, and they showed that growth arrest genes 
were not differently expressed (by reporter systems) when either PxxP-deficient-
p53 or WT p53 expression vectors were reintroduced into p53 null cell lines. 
They did find differences in apoptosis, however, when comparing the two 
variants that they accounted for by WT-p53 being much more proficient than 
PxxP-deficient-p53 in inducing p53-inducible-gene-3 (Pig3/Tp5i3) in reporter 
assays. They also noted decreased ROS production in cells with PxxP-deficient-
p53 as compared to WT-p53. As Pig3 may be involved in ROS production, 
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which may influence apoptosis, they suggested that the decreased induction of 
Tp5i3 was the mechanism for decreased apoptosis in cells with PxxP-deficient-
p5361. Another study found similar results. Although they saw decreased 
endogenous p21 and Mdm2 induction as a result of transfection with PxxP-
deficient-p53 as compared to WT-p53 transfection, they did not find evidence of 
decreased growth arrest. However, as in the earlier study, they found decreased 
apoptosis and decreased induction of ROS producing genes with PxxP-
deficient-p53 vector transfection. They similarly suggested that this decreased 
ROS production ultimately lead to decreased apoptosis in cells harboring of 
PxxP-deficient-p53 vectors62. Another study found increased affinity to Mdm2 
and increased susceptibility to Mdm2 mediated ubiquitination and nuclear 
export with PxxP-deficient p53 as compared to WT p53. This study also showed 
decreased apoptosis in cells transfected with PxxP-deficient-p53 as compared to 
WT-p53 transfected cells.  
 The general consensus, therefore, is that the proline rich domain of p53 
is probably dispensable for cell cycle arrest but necessary for inducing apoptosis 
when p53 is re-introduced into p53 deficient cell lines. However, the proposed 
cellular mechanisms for this effect vary by study 61-64. In addition to apoptosis 
induced by re-introduction of p53 vectors in p53 null cell lines, the PxxP domain 
appears to be necessary for apoptosis induced by most chemotherapeutics, at 
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least in cell culture65, suggesting that, by extension, it is involved in apoptosis by 
other genotoxic insults.  
The proline rich domain is contains the amino acids coded by the first 
discovered and by far most studied single nucleotide polymorphism (SNP) in the 
p53 gene… 
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1.2 The p53 codon 72 polymorphism (rs1042522) 
 
1.2.1 Discovery and early epidemiological studies of codon 72 
polymorphism  
 
Not long after the discovery of p53, several labs began noting that 
different human cell lines produced apparently different p53 protein species, as 
determined by polyacrylamide gel electrophoresis. Accordingly, cloning and 
sequencing revealed two different cDNA sequences at codon 72: CCC coding 
for proline and CGC coding for arginine 5,66-70. By 1990, PCR and enzyme 
digestion of DNA from 50 unrelated individuals provided evidence that these 
differences were (as had been previously suspected) not a mutation, but the first 
validated SNP in the p53 gene71. This polymorphism is often referred to as the 
p53 R72P polymorphism.  
An early report noted increased expression of the p53 R72P proline 
variant in ethnicities from equatorial regions as compared to ethnicities from 
northern latitudes72. Later, sequencing of the chimpanzee genome showed that 
only the proline variant is found in chimpanzees73, suggesting that the proline 
variant is the ancestral form. Together these studies point to evolutionary 
survival advantages for the arginine variant in northern latitudes, and some 
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speculate this could be tied to cancer risk associated with 
environmental/climatic differences74.   
In the early 1990s, while the tumor suppressor role of p53 was still being 
established, attempts at understanding whether the p53 R72P polymorphism 
had any function in cancer incidence were already being published. That year 
the first epidemiological study attempting to associate the polymorphism with 
cancer incidence found no difference between polymorphic variants in colon 
cancer75. Shortly thereafter, another study in acute myeloid leukemia also failed 
to find an association between either variant and cancer incidence76. At least six 
early studies in lung cancer incidence found largely disparate results; however, 
when an increased risk was found, it tended to be associated with the proline 
allele77-82. The Kawajiri et al. lung cancer study also looked at several other 
cancers and found that the arginine allele was associated with stomach cancers 
but found no association between p53 codon 72 genotypes and colorectal, 
bladder and breast cancers78. In agreement with Kawajiri et al., another study 
found no associations between p53 R72P variants in urologic cancers83. Unlike 
the Kawajiri et al. study, another report associated the proline variant with 
increased breast cancer incidence84. Two other early reports also failed to 
conclusively link cancer incidence with p53 R72P polymorphic alleles. One 
showed there was no association between p53 R72P genotype and 
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nasopharyngeal carcinoma85. Another showed that arginine homozygosity 
conveyed a survival advantage but also earlier age of onset in ovarian cancer86. 
In summary, the mixed results of epidemiological studies from the 90s indicate 
an inability to definitively associate one p53 R72P variant with increased cancer 
susceptibility.  
Such studies remained relatively unnoticed, however, when compared to 
the 1998 paper by Storey et al., which associated arginine coding homozygosity 
with increased cervical cancer risk. Storey showed greater p53 degradation of 
the arginine variant protein by E6 oncoproteins from the human papilloma virus, 
which he postulated as the mechanism for that difference87. Perhaps because it 
was the first report to suggest a mechanism for cancer incidence differences and 
to employ cell culture models in addition to an epidemiological study, Storey’s 
story catapulted the functional effects of p53 R72P polymorphism into the 
limelight74. Since Storey’s report, interest in the polymorphism’s role in cancer 
has not waned even though the effect of the polymorphism on cervical cancer 
incidence has been inconsistent across many studies88,89. This continued interest 
is evidenced by the fact that PubMed publications average over 36 per year 
between 1999 and 2015 using the search term “p53 codon 72 polymorphism 
cancer.” Following the intensification of interest in the polymorphism after 1998, 
the functional effects of the polymorphism on cancer development and 
	  	   16 
response to therapy can generally be divided into studies that focus on cell 
culture, epidemiology or mouse models.  
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1.2.2 The p53 R72P polymorphism: cell culture models 
 
In 1999, Thomas et al. was the first to show increased apoptosis in p53 
null cells transfected with arginine variant p53 as compared to proline variant 
p5390. Dumont et al. validated this observation in temperature-sensitive clone 
models of the two variants, but did not find that induction of p53 target genes 
differed between them. Their study attributed the increased apoptosis in the 
arginine variant to increased interaction with nuclear export factors, including 
Mdm2, and subsequent p53 mitochondrial localization91. Using estrogen-
receptor-fusion-polymorphic-variant proteins in p53 null cells, Pim and Banks 
also noted an increase in apoptosis upon 4-hydroxy-tamoxifen induction in the 
arginine variant and increased G-1 cell cycle arrest in the proline variant92. 
Sullivan et al. showed that, in p53 null cell lines, transfection with arginine variant 
p53 vectors increased apoptosis in response to the chemotherapeutics 
doxorubicin and cisplatin when compared to proline variant transfection. This 
study further demonstrated that this effect was a result of increased arginine 
variant DNA interaction at the transcription start sites of (and subsequent 
transcription of) the pro-apoptotic genes Puma, p53-effector-related-to-PMP-22 
(Perp) and actin-interacting-protein-1 (Aip1/Pdcd6ip)93. Using temperature 
sensitive p53 clones and various DNA repair models, Siddique and Sabapathy 
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showed that the proline variant p53 was better able to induce DNA repair genes 
p53R2 (Rrm2b), gadd45 and p48 (Ddb2) and more efficiently repair DNA 
damage. Incidentally, they also validated increased apoptosis when the arginine 
variant was re-introduced into p53 null cells as compared to the proline variant, 
but did not find the up-regulated Aip1 in the arginine variant noted in prior 
studies94. Bergamaschi et al. used polymorphic variant vectors in p53 null cells to 
show that the proline variant preferentially bound apoptosis-inhibiting-ankyrin-
repeats-SH3-domain-proline-rich-region-protein (iASPP) and that iASPP 
decreased p53 R72P proline variant activity at the pro-apoptotic Bax promoter, 
which coincided with decreased apoptosis induced by that variant95.  
The major consensus in these studies is that p53 codon 72 arginine 
variant protein is better at inducing apoptosis, at least in cell culture models 
where p53 is reintroduced into p53 null cell lines. The conflicting mechanisms 
for the polymorphism’s role in apoptosis underscore the fact that immortalized 
cell culture models have provided somewhat limited clarity into the role p53 
R72P polymorphism may play in modulating human cancer incidence and 
survival. Yet even that role is highly debatable, considering that epidemiological 
studies have failed to clearly define the role of the polymorphism in human 
cancer incidence, survival and adverse effects of therapy. 
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1.2.3 Epidemiological literature on effect of the p53 R72P 
polymorphism on cancer incidence, survival and 
treatment side-effects 
 
A 2009 review of p53 polymorphisms in cancer already highlighted the 
fact that the body of individual epidemiological studies on the effect of the p53 
R72P polymorphism on cancer incidence was vast, complex and contradictory. 
The review also mentioned that many association studies were plagued with 
issues in study design74; furthermore, others have suggested that the use of 
tumor tissue for genotyping may be introducing bias into these studies96. A 
comprehensive meta-analysis of 302 case-controlled studies associated 
increased risk for thyroid, gastric, head and neck cancers and hepatocarcinoma 
with the p53P72/P72 genotype. Nevertheless, odds ratio (OR) indicated low risk. 
Furthermore, these associations were contingent on the selection criteria for 
studies included in the meta-analysis, and they differed when associations were 
analyzed in different ethnic groups97. Other meta-analyses for individual cancer 
types often provided conflicting conclusions. For example, two recent breast 
cancer meta-analyses showed 1) no association98, 2) and increased risk with the 
proline allele (except in Asian populations, in which the arginine variant showed 
increased risk)99. 
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Epidemiological studies associating the p53 R72P polymorphism with 
side effects of therapy and cancer survival and are not nearly as numerous as 
incidence studies. For therapy side effects, a few studies have shown increased 
febrile neutropenia or neutropenia in p53P72/P72 breast and small cell lung cancer 
patients, respectively, when compared to p53P72/R72 and p53R72/R72 patients100,101. 
The trend in survival studies is for the R variant, in hetero- and/or homozygosity, 
to favor survival when compared to the P variant93,102-108. Of these studies, 
Tommiska et al. found that p53P72/P72 breast cancer patients exhibited decreased 
survival compared to p53P72/R72 and p53R72/R72 patients, and this held true for 
patients with tumors that had lost p53 expression108. The latter suggests that the 
increased survival of p53P72/R72 and p53R72/R72 patients may result not from the 
tumor itself, but from tumor micro- and macro-environmental differences in the 
patient.  
In short, the epidemiological literature is extremely inconsistent when the 
effect of the p53 R72P polymorphism on cancer incidence is studied. Some 
studies do point to the proline variant being more prone to increased side 
effects of therapy and less favorable for survival although the limited number of 
studies makes these results far from definitive.  
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1.2.4 Mouse models used in clarifying the functions of WT and 
mutant p53 and mouse models of the p53 R72P 
polymorphism 
  
Genetically engineered mice have been essential to elucidating the role 
of p53 in tumor suppression and other biological functions. The earliest p53 
mouse models were transgenic mice that expressed mutant p53 and were more 
prone to a wide spectrum of tumor types. Later, knock-out (KO) mice, with large 
deletions of the p53 gene were used to model the effects of p53 inactivation in 
human cancer. The majority of p53-/- mice succumb to early-onset lymphoma 
and soft tissue tumors while some develop other cancers. In mice heterozygous 
for the KO allele, tumor development is delayed compared to KO homozygous 
mice and accelerated compared to WT mice. The tumor spectrum in these mice 
tends toward lymphomas, soft tissue sarcomas and osteosarcomas. This reflects 
the tumor incidence in Li-Fraumeni syndrome, a familial cancer susceptibility 
syndrome associated with germline mutations in the p53 gene, making p53+/- 
mice an important model for this human genetic condition. These p53 KO mice 
were also essential for showing the defects in apoptosis associated with p53 
loss. Furthermore, they were used (together with Mdm2 KO mice) to confirm the 
importance of Mdm2 in p53 regulation. Humanized knock-in (KI) mouse models 
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of p53, in which portions of the mouse p53 are replaced with either WT or 
mutant human p53 have also been generated. These models provided 
important insights into the role of “hot-spot” mutations in the cancer 
development and progression (summarized from an excellent review by 
Donehower and Lozano 109). We believe humanized p53 knock-in (KI) mice can 
also be useful for understanding the role human SNPs in cancer development 
and treatment.  
 With over 80 million human SNPs currently known111, it is very difficult to 
determine the effect of a single SNP in epidemiological studies of cancer 
patients cohort, especially considering the environmental differences as well as 
differences in treatment that these patients undergo. For these reasons, our 
laboratory, and others, has looked to mouse models of the polymorphism to 
address the role of the polymorphism in cancer in-vivo in a more controlled 
manner than epidemiological studies can  
 Since the p53 R72P polymorphism is not conserved in mice (Figure 1.1 
a ), our laboratory created humanized mouse models of the two human SNP 
variants. In these mouse models, mouse exon 4 is replaced with the proline 
(codon 72 CCC) or arginine (codon 72 CGC) coding human exon 4 (Figure 1.1 
b ).  
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Zhu et al. used these models to study tissue-specific differences in 
apoptosis in p53P72/P72 and p53R72/R72 mice treated with ultraviolet and ionizing 
radiation (UV and IR), molecular pathways associated with apoptosis, and skin 
tumor induction in UV exposed p53P72/P72 and p53R72/R72 mice. In agreement with 
previous cell culture models, increased caspase-3 staining (an indicator of 
apoptosis) was noted by immunohistochemistry (IHC) in the intestine of IR-
treated p53R72/R72 when compared to tissues from p53P72/P72 mice. However, p21 
and p53 levels did not differ significantly between genotypes (Figure 1.2 ).  
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Figure 1.1 Mouse models employed. a) The p53 R72P polymorphism is 
in a region poorly conserved in mice. b) Schematic for constructs used to 
generate p53P72/P72 and p53R72/R72 mice as previously described.  
Zhu, F., Dolle, M. E., Berton, T. R., Kuiper, R. V., Capps, C., Espejo, A., McArthur, M. J., Bedford, M. T., van Steeg, H., 
de Vries, A. & Johnson, D. G. Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res 70, 
5851-5859, doi:10.1158/0008-5472.CAN-09-4646 (2010).  
Copyright license number: 3966081084889 
b	  
a	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Figure 1.2 Apoptosis in p53 R72P mice. p53P72/P72 and p53R72/R72 mice were 
treated with 6 Gy IR, sacrificed at 1.5 or 24 hours after treatment and intestinal 
tissue was taken and immunostained with a) p53, b) p21 and caspase-3. Average 
number of positive cells for 10 mm of intestine are represented. *p=<0.05 
Zhu, F., Dolle, M. E., Berton, T. R., Kuiper, R. V., Capps, C., Espejo, A., McArthur, M. J., Bedford, M. T., van Steeg, H., 
de Vries, A. & Johnson, D. G. Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res 70, 
5851-5859, doi:10.1158/0008-5472.CAN-09-4646 (2010).  
Copyright license number: 3966081084889 
c
a	  
b	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In our models, Puma, Perp and Noxa mRNA levels and mitochondrial 
localization of p53 were both increased in p53R72/R72 mouse primary fibroblasts 
exposed to UV when compared to p53P72/P72 fibroblasts exposed to UV, but p21 
mRNA levels were not affected. Surprisingly, there were no differences in skin 
tumor growth in UV exposed mice across genotypes, suggesting that differences 
in immediate apoptotic response to UV might not predict future tumor 
growth112. 
 Our lab also generated bacterial artificial chromosome (BAC) models in 
which mice with the entire human p53 gene of either the P or R coding variant 
were crossed into p53 KO mice. In both variants, mice produced functional p53 
that rescued them from the early-onset lymphoma seen in p53 KO mice without 
the BAC transgene. However, when the BAC models were used to study 
spontaneous tumor incidence, no statistically significant differences were found 
between R and P variants in overall survival and only a few differences in tumor 
spectrum were noted112.    
Maureen Murphy’s laboratory generated and used other mouse models 
of the R72P polymorphism that replace exons four to nine of mouse p53 with 
the codon 72 arginine or proline coding human variant exons 113,114. Employing 
these models, they found comparable levels of p53 protein, Mdm2 and Puma 
mRNA, but increased levels of p21 protein and p21 mRNA in p53P72/P72 MEFs 
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exposed to genotoxic insult compared to p53R72/R72 MEFs. Additionally, this study 
found IR treatment caused increased apoptosis in p53P72/P72 mouse thymus 
compared to p53R72/R72 mouse thymus by IHC. There was no up-regulation of the 
pro-apoptotic genes Puma, Noxa, Bax and p53-induced-death-domain-protein-
1 (Pidd) in cultured p53P72/P72 thymocytes exposed to IR compared to p53R72/R72 
thymocytes. However, there was an up-regulation of p21 and several NF-κB 
target genes in IR-exposed p53P72/P72 thymocytes compared to p53R72/R72 
thymocytes. Most notably, Caspase 4/11 which has functions in both pro-
inflammatory and pro-apoptotic signaling was upregulated in the proline variant. 
Accordingly, this study also showed that NF-κB subunit p65 RelA had increased 
interaction with p53P72 protein when compared to the arginine variant. 
Furthermore, in a survival study, p53P72/P72 mice appeared to be more susceptible 
to lipopolysaccharide (LPS) injection: a model for acute inflammatory response, 
such as that noted in septic shock. Taken together, this study suggests that the 
proline variant may be more likely to mount an inflammatory response than the 
arginine variant. Almost no difference in cancer incidence or latency was noted 
between the two variants in two separate genetic models of cancer induction: 
one using Eμ-myc-p53P72/P72 and p53R72/R72 mice and another using p53P72/- and 
p53R7/- mice115. These data, like ours, suggest that the polymorphism is not a 
strong predictor of cancer risk. Also in agreement with our findings, the Murphy 
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laboratory later reported increased apoptosis in IR exposed p53R72/R72 mouse 
intestine 116.  
In another study from our laboratory, Sarkar et al. crossed p53P72/P72 and 
p53R72/R72 mice with K14-HPV16 mice –which express E6 and E7 oncoproteins 
from HPV viruses under the K-14 promoter – to test the effect of the 
polymorphism in a model of HPV infection. This allowed us to model 
carcinogen-induced (4-Nitroquinoline 1-oxide/4NQO) oral cavity and 
esophageal cancers in the context of HPV infection. Using this model, we 
showed esophageal cancer incidence and multiplicity were all greater in 
p53P72/P72-K14-HPV16 mice compared to p53R72/R72 -K14-HPV16 mice exposed to 
4NQO. There was no significant difference in incidence of cancer of the oral 
mucosa between genotypes but survival was attenuated in p53P72/P72 -K14-HPV16 
mice, suggesting shorter tumor latency. In addition, there were significantly 
increased neutrophil counts, white blood cell counts (WBC), serum globulin 
levels and inflammatory cell infiltrates in esophageal tumors in p53P72/P72-K14-
HPV16 mice exposed to 4NQO when compared to p53R72/R72 -K14-HPV16 mice 
and tumor tissues117. This study reinforced the Murphy laboratory’s conclusion 
that genotoxic stress may result in increased inflammation associated with the 
proline allele in some tissues.  
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Unpublished data from a pilot study in our laboratory also showed what 
appeared to be increased sensitivity to IR in p53P72/P72 mice compared to 
p53R72/R72 mice, which suggested p53P72/P72 mice might be more sensitive to 
adverse effects from ionizing radiation (IR), a commonly used genotoxic cancer 
therapy (Figure 1.3 )  
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Figure 1.3 Different IR tolerance in p53 R72P variant mice. Young 
p53P72/P72 and p53R72/R72 and WT mice were treated with 6 Gy IR and followed to 
morbidity: p53P72/P72 vs. p53R72/R72 log rank test p=0.03  
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1.3 The importance of mouse strain background 
 
Mouse background strain has long been known to affect IR sensitivity. 
Over 50 years ago it had been shown that, of the mouse strains employed at the 
time, the radio-resistant 129/J strain survived twice as long as the more radio-
sensitive CBA/J following radiation exposure. Furthermore, the LD50.30 dose of 
radiation (i.e. the dose that killed 50% of mice by 30 days) was almost 2 Gy 
higher for 129/J mice compared to Balb/cJ mice118,119. 
 Later studies showed that background strain may even alter radiation-
induced apoptosis and target gene expression. These studies suggested that, 
upon exposure to equal doses of IR, the more radio-sensitive DBA/2 strain 
exhibited less IHC staining for markers of apoptosis in some tissues when 
compared to the more radio-resistant C57BL/6 strain. Furthermore following IR, 
the DBA/2 strain seemed to have decreased pro-apoptotic Bax protein, and 
increased p21 protein by western blot and IHC, at least in some tissues and at 
some time points120-122.  
For prior studies in our laboratory, we had backcrossed our p53 R72P KI 
mice for several generations to mice with the FVB and SKH (hairless) 
background. However, when we employed our Animal Genetics Core to 
perform marker assisted background characterization123, we found that the 
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presumably FVB mice intended for future study still had mixed genetic 
backgrounds. We therefore collaborated with our Animal Genetics core to use 
marker assisted background characterization for maximizing the percentage of 
FVB background. In a process referred to as “speed congenics,” p53P72/P72 and 
p53R72/R72 mice with the highest number of FVB genetic markers were crossed to 
WT FVB mice. The resulting p53P72/WT and p53R72/WT heterozygous progeny were 
chosen for further backcrossing by again choosing those mice with the most FVB 
markers. We continued this process until both p53P72/WT and p53R72/WT mice were 
greater than 99% FVB and then bred these mice to homozygosity for the 
purposes of this dissertation project. To prevent genetic drift in our population, 
homozygous p53P72/P72 and p53R72/R72 mice and/or heterozygous p53P72/R72 mice 
were periodically outbred to recently acquired (from commercial facilities) FVB 
WT mice before being bred back to p53P72/P72 and p53R72/R72 homozygosity.  
 
 
 
 
 
 
 
	  	   33 
1.4 Hypothesis  
 
The role of the p53 R72P polymorphism in human cancer is not well 
defined. Cell culture models suggest that the polymorphism affects apoptosis, 
with the cells expressing the R variant showing greater apoptosis in response to 
a wide variety of chemotherapeutics and IR. Nevertheless, epidemiological 
studies of cancer incidence fail to consistently show a major effect for the role of 
the p53 R72P polymorphism. Yet, limited epidemiological studies of survival 
differences and differential effects of cancer therapy consistently suggest that 
the proline variant negatively influences outcome and adversely affects therapy 
tolerence93,100-108. Furthermore, this may not depend on the expression of p53 in 
the tumor108 suggesting that non-tumor cell autonomous differences may 
account for this survival effect.  
Two different mouse models of the p53 R72P SNP from two labs were 
able to show similar tissue specific induction of increased apoptosis in intestinal 
tissue in IR treated p53R72/R72 mice when compared to IR treated p53P72/P72 mice. 
Data showing that genotoxic insult may increase the inflammatory response in 
p53P72/P72 mice compared to p53R72/R72 mice115,117 provide preliminary evidence 
that differences in the tumor macro- and micro-environment may be mediating 
treatment and survival effects seen in human epidemiological studies. In 
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addition, our pilot study of IR sensitivity suggested that p53P72/P72 mice are more 
sensitive to genotoxic insult, which supports the limited epidemiological 
evidence that patients with the proline variant of the polymorphism are more 
susceptible to adverse effects of cancer therapy. However, genes upregulated 
following genotoxic treatment were not always consistent across mouse studies 
or immortalized cell culture models, suggesting that mechanisms for any 
differences need to be further studied in primary cell cultures or in-vivo. In these 
mouse models, the evidence for differences between these polymorphic variants 
in tumor induction under oncogenic stress is much weaker than the evidence for 
differences in response to genotoxic insult.  
Considering these data, it appeared that our mouse models of the 
polymorphism were best suited for studying tissue specific responses and 
tolerance of genotoxic cancer therapies. For this project I hypothesized 
that the p53 R72P polymorphism modulates adverse effects of 
genotoxic cancer therapy by tissue specific regulation of pro-
apoptotic and/or pro-inflammatory gene expression. The novelty of 
this project is employing KI mouse models of a common human polymorphism 
as a pre-clinical assessment of how some adverse effects of genotoxic therapy 
may be modulated by the R72P polymorphism.  
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Chapter 2: 
The Role of the p53 R72P Polymorphism 
in the Adverse Effects of Doxorubicin 
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2.1  Introduction  
 
Differences in cancer remission and survival following anthracycline-based 
chemotherapies are epidemiologically linked to differences in the p53 R72P 
genotypes102,124. Although polymorphism-specific differences in p53-driven gene 
expression of pro-inflammatory and anti-apoptotic gene expression have been 
noted115,125, a comprehensive in vivo study to identify mechanisms for these 
differences has not been performed.  
This study sought to test the effects of anthracyline therapy in our mouse 
models of the p53 R72P SNP. By using mouse models, we could analyze 
systemic effects that cannot be studied in cell culture while still controlling for 
genetic and environmental differences found in epidemiological studies. We 
chose to focus on an RNA-sequencing experiment to analyze gene expression 
as the most unbiased and comprehensive approach to understanding 
differences in gene expression between p53P72/P72 and p53R72/R72 mice. We chose 
doxorubicin exposure as a model chemotherapeutic as it is known to induce 
DNA damage and acute inflammation126-128 and is used in treatment regimens 
for many cancers128. Thus, doxorubicin tolerance may be a factor in the 
differential survival and response to therapy patterns noted in human population 
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studies of the polymorphism. We used a dose of 5 mg/kg doxorubicin, which is 
considered a therapeutic dose in mouse models of tumor response129.  
RNA sequencing was used to investigate differences in gene expression 
between p53P72/P72 and p53R72/R72 mice upon exposure to doxorubicin in two 
tissues: thymus and liver. We chose to analyze the thymus as data from a p53 
R72P mouse model showed differential gene expression patterns in thymocytes 
in response to genotoxic insult115. Furthermore, the thymus is important for re-
establishing T-cell populations after lymphotoxic treatments in cancer 
patients130. We chose the liver since it is the primary organ for doxorubicin 
metabolism131,132. Blood tests were also performed to determine whether there 
would be differences in several white blood cell (WBC) numbers, a possible side 
effect of doxorubicin chemotherapy in humans133. 
Surprisingly, very few differences in gene expression between genotypes 
were found in treated and untreated mice. Additionally, we could not confirm 
that the doxorubicin dose we employed had elicited adverse effects on 
leukocyte numbers or body weight change, suggesting we needed to adjust the 
dose. Therefore, we later conducted a toxicology experiment on WT FVB mice 
to attempt to determine a dosing regimen that would elicit blood count or 
weight changes in FVB mice. This study also showed few quantifiable differences 
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in blood counts or weight at any dose between saline and doxorubicin treated 
mice, suggesting that FVB mice may be resistant to doxorubicin toxicity.  
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2.2 Materials and Methods 
 
Mice and cell l ines used: 
Generation of p53P72/P72 and p53R72/R72 knock-in mice is described 
elsewhere112. To avoid potential influence of mouse strain on phenotypes, we 
backcrossed to FVB mice until they were >99% FVB using marker-assisted 
background characterization123. We generated mouse adult fibroblasts (MAFs) 
from adult p53P72/P72 and p53R72/R72 mice by mincing peritoneal tissue and 
subjecting the tissue to collagenase and trypsin digestion before growing the 
cells to confluence in DMEM with 10%-20% FBS. MAFs were passaged a 
maximum of five times. 
 
Doxorubicin treatment: 
For blood counts and RNA sequencing studies, at approximately six 
weeks of age, female p53P72/P72 and p53R72/R72 mice were injected 
intraperitoneally (IP) with either doxorubicin diluted in normal saline to 0.2 
mg/ml, at a dose of 5mg/kg, or the equivalent volume of normal saline for 
control mice. Mice were weighed prior to treatment and seven days after the 
first treatment.  
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For the doxorubicin toxicity study, young female WT FVB mice were 
purchased (Harlan/Envigo, Indianapolis, IN, USA). When mice were 
approximately 100 days old, they were divided in to five treatment groups of 
eight mice for the different doxorubicin doses. These treatment groups were as 
follows:  
Group Treatment Dose (mg/Kg) Frequency Duration 
1 Saline N/A Every 48 hours 3 treatments 
2 Doxorubicin 2.5 Every 48 hours 3 treatments 
3 Doxorubicin 5.0 Every 48 hours 3 treatments 
4 Doxorubicin 7.5 Every 48 hours 3 treatments 
5 Doxorubicin 10.0 Once 1 treatment 
 
Mice in groups 1-5 were weighed prior to the first injection and after the 
third injection. Mice that exhibited unexplained morbidity or death prior to the 
completion of the study were excluded.  
 
RNA isolation and sequencing: 
Mice were treated once weekly for two weeks with 5mg/kg doxorubicin 
or saline controls were sacrificed by CO2 inhalation 24 hours following the final 
injection. Liver and thymus were extracted and immediately frozen in liquid 
nitrogen until RNA extraction. RNA was extracted with RNEASY kit with DNA 
digestion (Qiagen, Hilden, Germany) as per manufacturer’s protocol. Synthesis 
	  	   41 
of cDNA and sequencing was performed in our Molecular Biology Core using 
the Illumina HiSeq 2000. Our Bioinformatics Core analyzed the data: briefly, they 
mapped reads to reference sequences using TopHat 134, and quantified 
differential expression using the R/Bioconductor package 135.  
 
Doxorubicin toxicity, histopathology: 
Two mice from each treatment group were sacrificed at 96 hours 
following the final treatment, necropsied and tissues were fixed in 10% buffered 
formalin. H & E staining was carried out using a Shandon Varistain Gemini 
automatic stainer (ThermoFischer Scientific, Waltham, MA, USA). Slides were 
read by our Veterinary Pathologist. 
 
Blood counts: 
For monitoring blood counts, 100 uL of blood was drawn from live 
approximately p53P72/P72 and p53R72/R72 mice by saphenous vein bleed prior to 
doxorubicin or saline injection and following treatment at the time-points 
indicated. Blood was collected in sodium EDTA micro-tubes and counted using 
the Hemavet 950 hematology system (Drew Scientific, Miami Lakes, FL, USA).  
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Reverse transcription and quantitative PCR (q-PCR)  
cDNA was generated using the SuperScript® II Reverse Transcriptase kit 
(Invitrogen, Carlsbad, CA, USA) as per manufacturer’s instructions. Quantitative 
PCR was carried out using the following primer sets: 
Cxcl1: For. 5’TTAGGGTGAGGACATGTGTGG3’ Rev. 5’TGCCCTACCAACTAGACACA3’ 
Inhbb: For. 5’AACAATCCTTCGAGTGGCCT3’ Rev. 5’CAGCACACACCTTCACTCCA3’ 
Tgtp1: For. 5’	  AGGCATGTAAGCACCTCCAC3’ Rev. 5’GGACAGAGAGGCAGGTTCAC3’ 
 For Xaf1, PrimePCR™ SYBR® Green Assays qMmuCID0009205 and 
qMmuCED0049379 (Biorad, Hercules, CA, USA) were used. 
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2.3  Results 
 
2.31  RNA sequencing in doxorubicin treated and untreated 
p53 R72P mice: 
 
RNA sequencing was carried out on thymus and liver of six-week-old 
p53P72/P72 and p53R72/R72 mice treated with saline or doxorubicin once weekly for 
two weeks and sacrificed 24 hours following the final injection. For RNA 
sequencing data, we only considered genes with a false discovery rate (FDR) of 
0.05 or less and a minimum of a two-fold difference between genotypes.  
RNA sequencing of the thymic tissues revealed only one well-
characterized gene differentially regulated per this criteria across genotypes: X-
inhibitor-of-apoptosis-associated-factor-1 (Xaf1). Xaf1 was of interest to our 
study, as it is generally considered a negative regulator of inhibitor-of-apoptosis 
(IAP) protein family members, and has been implicated in modulating p53 
apoptotic signaling upon some genotoxic insults136. By RNA sequencing, Xaf1 
had 2.6-fold greater expression in doxorubicin treated p53R72/R72 thymus as 
compared to doxorubicin treated p53P72/P72 thymus. However, Xaf1 was similarly 
up-regulated in both treated and untreated p53R72/R72 thymus, compared to 
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untreated p53P72/P72 thymus, suggesting that this allelic difference was not 
induced by doxorubicin treatment.  
We attempted to use reverse transcription (RT) and q-PCR to confirm this 
difference in expression from the thymic RNA used in sequencing samples and a 
second biological replicate. In agreement with the RNA-Seq data, we found a 
highly significant increase in Xaf1 expression in p53R72/R72 mouse thymus 
compared to p53P72/P72 thymus regardless of treatment, and this difference was 
not significant between treatment groups. We also found this difference in RNA 
expression in untreated and IR treated p53P72/P72 and p53R72/R72 MAFs.  
Nevertheless, in experiments with a second Xaf1 primer set, Xaf1 q-PCR 
did not show significant differences between genotypes. This implied that the 
initial results might have been an artifact and not the actual Xaf1 gene. Indeed, 
DNA sequencing of PCR fragments revealed what appeared to be an artifact 
using the first primer (that showed a large difference between genotypes) 
(Figure 2.1a ). Sequencing also revealed that the second primer (which 
showed little difference between genotypes) produced a fragment of the correct 
size and sequence to be representative of actual Xaf1 gene expression. 
Furthermore, q-PCR of proprietary Biorad positive control synthetic DNA did not 
show amplification of Xaf1 using the first primer (that showed a difference in 
Xaf1 expression between genotypes). On the other hand, there was strong 
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amplification of Xaf1 using the positive control synthetic DNA with the second 
primer (that did not show a difference in Xaf1 gene expression between p53 
R72P genotypes) (Figure 2.1b ). Taken together, these data suggested that an 
RNA artifact, not representative of actual Xaf1 gene expression, was being 
differentially amplified in the initial RNA sequencing and in the q-QCR results 
(which had shown increased Xaf1 expression in p53R72/R72 MAFs). Considering 
this, we decided not to further pursue studying Xaf1 expression in our mouse 
models of the p53 R72P polymorphism.  
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Figure 2.1 Xaf1 expression in p53 R72P MAFs.  q-PCR on cDNA from 
untreated MAFs using the Xaf1 primers that a) amplified artifact cDNA, and b) 
amplified the actual Xaf1 cDNA 
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In treated liver, only eight genes were found to have two fold or greater 
difference in expression between genotypes and an FDR of less than 0.05 and 
only five had well defined functions. Of those, three were involved in 
inflammation. Differences in transcriptional regulation of inflammatory genes 
have been seen in other tissues in another mouse model of the p53 R72P 
polymorphism115. Therefore, we attempted validation by RT and q-PCR on these 
genes. q-PCR on cDNA synthesized from the liver RNA used for the RNA-Seq 
experiment did not confirm the differences seen by RNA-Seq (Table 2.1 ). Due 
to the paucity of differences in gene expression by RNA-Seq between 
genotypes in thymus and liver, we decided not to further pursue differences in 
gene expression induced by doxorubicin.  
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Table 2.1 Summary of RNA sequencing and q-PCR validation. A list 
of genes differently regulated in the liver of p53P72/P72 and p53R72/R72 mice treated 
once weekly for two weeks with doxorubicin 5mg/kg and sacrificed 24 hours 
following the final treatment. Genes associated with inflammation are 
highlighted in red.  
 
 
 
 
Locus Gene Function
Expression0
increased0in0 Fold0change pvalue FDR
Q:PCR0supports0
RNA0sequencing?
chr7:104768049,104777470 Usp17le deubiquitylase P/P
chr5:90891245,90893115 Cxcl1
chemokine,FneutrophilF
attraction,Fangiogenesis,F
woundFhealing,Finfection,F
tumorigenesisF
P/P
chr1:119415465,119422248 Inhbb
normallyFFSHFinhibitor,FalsoF
relatedFanemiaFofF
inflammationFviaFactivationF
ofFhepcidinFinFliver
P/P
179.635427 1.64E,05 0.02 ND
6.12892169 8.74E,06 0.02 NoF
2.8077116 3.18E,06 0.02 No
chr17:3326573,3519397 Tiam2 neuralFdevelopmentF R/RF
chr11:48985329,48992246 Tgtp1
interferonFgammaFinducedF
gene R/R
3.93065176 2.37E,05 0.03 ND
9.08815308 4.44E,05 0.05 No
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2.3.2  Blood counts and weights in doxorubicin treated and 
untreated p53 R72P mice 
Treating mice once with 5mg/kg of doxorubicin resulted in little change 
in WBC, neutrophil or lymphocyte counts one week after treatment compared to 
saline treated mice. There were minimal differences between genotypes and 
between treatment groups prior to treatment, and no significant differences 
between genotypes or between treatment groups after treatment (Figure 2.2 ). 
Furthermore, body weights were not affected by this dose (Figure 2.3 ). These 
data suggested that the doxorubicin dose of 5 mg/kg caused minimal systemic 
adverse effects in FVB mice. 
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Figure 2.2 Hematology in p53 R72P mice untreated or treated 
with doxorubicin. Minimal differences between genotypes and treatment 
groups in hematology performed on p53P72/P72 and p53R72/R72 mice treated once 
with doxorubicin 5mg/kg or saline seven days after treatment  
two-sided independent t-test 
* p<0.05). 
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Figure 2.3 Weights of p53 R72P mice untreated or treated with 
doxorubicin. No differences between treatment groups or genotypes in 
weights of p53P72/P72 and p53R72/R72 mice treated once with doxorubicin 5 mg/kg 
or saline seven days after treatment.  
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2.3.3  Doxorubicin toxicity study in WT FVB mice 
 
The above studies pointed to the lack of quantifiable adverse effects of 
doxorubicin at a dose of 5 mg/kg weekly, at least in FVB mice. Therefore, we 
decided to attempt to find a dosing regimen and time frame that would elicit 
measurable adverse effects in WT FVB mice prior to continuing study on the p53 
R72P polymorphic mice. To this effect, same-aged, adult FVB WT female mice 
were treated with one of five dosing schedules: 1) saline only every 48 hours for 
three doses, 2) doxorubicin 2.5 mg/kg every 48 for three doses, 3) doxorubicin 
5.0 mg/kg every 48 hours for three doses, 4) doxorubicin 7.5 mg/kg every 48 
hours for three doses, or 5) doxorubicin 10.0 mg/kg for a single dose. Blood 
counts were performed in all treated mice at 72 hours following the final 
treatment. Weight changes and histopathological tissue changes were analyzed 
in a subset of mice.  
Blood counts at 72 hours following the final dose failed to show 
significant differences between treatment groups, with the exception of an 
increase in neutrophil counts in mice treated at 5.0 and 7.5 mg/kg doses 
described above (Figure 2.4 ). A significant difference in weight was noted 
between the saline treated mice and those treated with 5.0 and 7.5 mg/kg 
	  	   53 
doxorubicin following the third treatment; however, there were also significant 
differences between groups prior to treatment (Figure 2.5 ). 
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Figure 2.4 Hematology in WT FVB treated untreated or treated 
with doxorubicin. Minimal differences between treatment groups in 
hematology performed on WT FVB mice treated every 48 hours for three doses 
with saline, doxorubicin 2.5 mg/kg, 5.0 mg/kg, or 7.5 mg/kg or a single dose of 
doxorubicin 10 mg/kg at 72 hours after final treatment  
two-sided independent t-test 
* p<0.05, ** p<0.005 
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Figure 2.5 Weights of WT FVB mice untreated or treated with 
doxorubicin. Differences in weight in WT mice treated with saline or 
doxorubicin at 2.5, 5.0, or 7.5 mg/kg prior to initial treatment (Day 0) and prior 
to the third treatment (Day 5) 
two-sided independent t-test 
* p<0.05, ** p<0.005 
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Histological analysis of tissues by our veterinary pathologist from a subset 
of mice revealed some qualitative differences, especially in mice treated with 
higher doses of doxorubicin. Mice treated with 7.5 mg/kg doxorubicin for three 
doses and mice treated with 10 mg/kg doxorubicin for one dose showed mild 
cardiomyocyte degeneration, a well-established adverse effect of doxorubicin 
therapy137. Mice treated with 7.5 mg/kg for three doses exhibited intestinal 
villous atrophy. Although cortical thymus atrophy was noted in all mice treated 
with doxorubicin, there was no evidence of increased apoptosis in splenic 
lymphocytes, suggesting that the thymic atrophy may have been a stress 
response and not a direct result of doxorubicin toxicity. Consistent with the 
minimal differences noted in blood counts, there was little histological evidence 
of bone marrow depletion in any treatment group.  
Although the histopathology report and weight loss data did indicate 
some adverse effects of doxorubicin therapy at higher doses in FVB, these 
differences were not marked and were mainly qualitative. Furthermore, the lack 
of differences in blood counts between treatment groups, and limited 
indications of apoptosis in any tissue of doxorubicin treated FVB mice 
suggested that further study with doxorubicin would not generate quantifiable 
data. Therefore, we decided not to further pursue differences in adverse effects 
of doxorubicin therapy using our p53 R72P polymorphic mice.  
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2.4 Discussion 
 
In this study we examined whether the p53 R72P polymorphism 
modulated the response to doxorubicin toxicity as a model of genotoxic cancer 
therapy. We sought to determine whether differences noted in gene expression 
upon doxorubicin therapy would correlate with physiological phenotypes of 
weight loss and reduced blood cell counts.  
When mice were treated with doxorubicin at 5 mg/kg for two weekly 
treatments, RNA sequencing only revealed one gene differentially expressed in 
thymus of p53P72/P72 and p53R72/R72 mice, Xaf1. However, further investigation 
indicated that this difference was likely attributable to an artifact transcript, as 
only one primer (a primer which did not work for positive control synthetic DNA) 
was able to confirm any difference in Xaf1 expression between genotypes. 
There were only five characterized genes differentially upregulated in the liver: 
none were associated with apoptosis, but three were associated with 
inflammation. Nevertheless, q-PCR failed to validate differences in their 
expression. The paucity of genes found precluded pathway analysis. 
Furthermore, it indicated that there were very few differences in gene 
expression between genotypes in our mouse models of the polymorphism when 
mice were exposed to the genotoxic agent doxorubicin.  
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Blood counts and weight were unaffected by this dose of doxorubicin, 
making comparison of physiological response between p53 R72P variants 
challenging. To attempt to find a dose of doxorubicin that would induce 
quantifiable differences in blood counts and weight, and qualitative differences 
in histology, we attempted a toxicity study in WT FVB mice. However, even at 
the highest doses, doxorubicin induced only minimal changes in weight and no 
significant decreases in blood cell counts. Furthermore, histological changes 
were minimal. Therefore, it seemed that using doxorubicin exposure in FVB 
mice was a poor model to assess the adverse effects of genotoxic cancer 
therapy. Since we had evidence that another genotoxic therapy, IR, produced 
much more quantifiable differences in gene expression and tissue damage112, 
we chose to study how the p53 R72P polymorphism modulates adverse effects 
of cancer therapy using IR.  
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Chapter 3: 
The Role of the p53 R72P Polymorphism in 
the Adverse Effects of Ionizing Radiation 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   60 
3.1  Introduction  
 
Given that the above data suggested that doxorubicin was not eliciting 
quantifiable adverse effects in FVB mice, we decided that differential response 
to IR treatment may serve as a better model for how the p53 R72P 
polymorphism modulates therapy side effects. The genotoxic effects of IR are 
well established. At a cellular level, IR induces DNA double strand breaks (DSBs) 
in addition to other forms of DNA damage. This damage is done directly or 
through the generation of ROS. In tissues sensitive to ionizing radiation, such as 
intestinal epithelia and hematopoietic cells, and in tumors bearing WT p53, 
DSBs result in apoptosis, often through induction of pro-apoptotic genes by p53 
138.  
IR is widely used for cancer therapy, and at MD Anderson 
(mdanderson.org), it is used as a treatment of at least 50% of cancers. IR therapy 
can involve total body irradiation (TBI) or more targeted therapies. TBI is often 
used in hematologic malignancies as a myleoablative treatment before 
hematopoietic stem cell transplant139. Localized treatment can sometimes induce 
systemic effects as well. Myeloblation can occur as an acute side effect of 
thoracic vertebrae IR therapy when large sections of bone marrow are exposed 
to IR. This can lead to neutropenia, leukopenia and thrombocytopenia 140. Other 
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acute side effects of high dose radiation include gastrointestinal disorders: TBI 
can induce nausea and vomiting139, while IR that targets the pelvic region can 
induce mucositis with diarrhea and cramping141.  
Histopathological changes evident in mice exposed to IR are in line with 
these patient symptoms. In mice, whole body irradiation is associated with 
histological changes such as decreased cellularity and accumulated nuclear 
debris in bone marrow, shortened villi in the small intestine and, in some cases, 
ulceration of the small intestine118. These data suggest that mice treated with 
whole body IR may serve as a model organism for the adverse effects of IR 
therapy in cancer patients.  
Understanding the role of the p53 R72P polymorphism in adverse therapy 
effects could have implications for personalized medicine, especially in the field 
of radiogenomics. Radiogenomic studies focus on how naturally occurring 
polymorphisms influence tumor response to radiation and the adverse effects of 
IR therapy in patient populations. Current research in this field employs 
case/control studies and genome wide association studies (GWAS) to 
characterize the effects of gene variants on IR therapy (reviewed in 142-144). 
Radiogenomic studies of the p53 R72P polymorphism are limited to two studies. 
One study found an increase in late skin complications of patients harboring the 
proline allele 145 although an earlier study had found the polymorphism did not 
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significantly affect acute skin damage following similar treatment 146. Given this 
lack of epidemiological information and the fact that published and unpublished 
data from our laboratory (Figures 1.2 & 1.3, Chapter 1 ) and others 
suggested that there were differences not only in immediate apoptotic 
response, but also in longer-term survival between IR treated p53 R72P mice, we 
decided to use these mouse models in preclinical testing of how the p53 R72P 
polymorphism impacts IR toxicity. We tested the differential effects of IR therapy 
on adult p53P72/P72 and p53R72/R72 mice measuring blood counts, body and tissue 
weight changes, histomorphological changes and long-term survival studies.  
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3.2 Materials and Methods  
 
Mice used: 
Generation of p53P72/P72 and p53R72/R72 KI mice is described elsewhere 112. 
To avoid potential influence of mouse strain on phenotypes, we backcrossed KI 
mice to FVB mice until they were determined to be >99% FVB, using marker-
assisted background characterization 123. To avoid the possibility that differences 
in development could account for phenotypes, we only used adult mice 
approximately 15 weeks old, and to control for differences between sexes, mice 
were sex-matched for each experiment, or an equal number of mice from each 
sex were employed.  
 
IR survival studies: 
Mice were subjected to X-ray IR at doses described below using an RS 
2000 Biological Research Irradiator (RadSource, Suwanee, GA, USA). 
Approximately 15-week-old p53P72/P72 and p53R72/R72 mice were treated with 6.135 
Gy IR. Mice were weighed, transferred to sterile housing and treated with 
prophylactic antibiotics (Clavamox: 50mg/ml amoxicillin and 12.5mg/ml 
clavulanic acid) in their drinking water. We monitored mice daily, weighed mice 
weekly and sacrificed mice exhibiting morbidity.  
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Western Blots: 
Cells from spleen were forced through a cell filter into cold PBS and 
pelleted. The pellets were lysed with RIPA Lysis Buffer System (#SC-24948, 
Santa Cruz Biotechnology, CA, USA). Western blot was performed on lysates 
with primary anti-p53 antibody A-1 (#SC-393031, Santa Cruz Biotechnology, CA, 
USA, 1:500 dilution, 4°C overnight) and secondary antibody m-IgGκ BP-HRP 
(#SC-516102, Santa Cruz Biotechnology, CA, USA, 1:5000 dilution, room 
temperature (RT) 1 hour). Membranes were washed and re-probed with anti-
GAPDH antibody (MAB374, Millipore Sigma, Darmstadt, Germany 1:5000 
dilution, 4°C overnight) and rabbit anti-mouse secondary antibody (#SC-358914 
Santa Cruz Biotechnology, CA, USA, 1:10,000 dilution, RT, 1 hour).  
For MAF lysates, primary antibodies anti-p53 CM5 (#VP-P956, Vector 
Laboratories, Burlingame, CA, USA, 1:1000 dilution, 4°C overnight) or anti-
phospho-p53 (Serine 15) (CST-#9284, Cell Signaling Technology, Danvers, MA, 
USA, 1:1000 dilution, 4°C overnight) and donkey anti-rabbit secondary antibody 
(#NA934, GE Healthcare UK Limited, Buckinghamshire, UK, 1:10,000, RT, 1 
hour) were used. Membranes were stripped and re-probed with anti-β-actin 
clone AC-15 (#A1978, Sigma-Aldrich, Darmstadt, Germany, 1:10,000, room 
temperature, 30-60 minutes) and rabbit anti-mouse secondary (#SC-358914, 
Santa Cruz Biotechnology, CA, USA, 1:10,000 dilution, RT, 30-60 minutes).  
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Density of protein bands on film was determined using ImageJ software 
(https://imagej.nih.gov/ij/). 
 
Reverse transcription (RT) and quantitative PCR (q-PCR): 
Cells from thymus were forced through a cell filter into cold PBS and 
pelleted. RNeasy Plus Mini Kit (Hilden, Germany) was used, as per 
manufacturer’s instructions to remove genomic DNA and extract RNA. cDNA 
was generated using the SuperScript® II Reverse Transcriptase kit (Invitrogen, 
Carlsbad, CA, USA) as per manufacturer’s instructions. Quantitative PCR was 
carried out using the primers: 
 p21- 5’AATACCGTGGGTGTCAAAGC3’ & 5’GTGTGAGGACTCGGGACAAT 3’ 
Mdm2-5’AGGAAGCGAAGGATAGCTTTG3’ & 5’CACCGCCTCCTATTCAAATG3’ 
Noxa-5’TCAGCATGTGTATCCGTTTCA3’ & 5’CCTTAATGCTGAGGCCCACT3’,  
Puma-5’ TGTGACCACTGGCATTCATT3’ & 5’CCCAGACTCCTCCCTCTTCT3’. 
  PrimePCR™ SYBR® Green Assays qMmuCID0007961 was used for 
Perp, qMmuCID0006274 for Bax and qMmuCID0006264 for was used p53 
(Biorad, Hercules, CA, USA). All gene expression values were normalized to the 
average value of P/P untreated mice. 
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Post-IR blood counts and blood clinical chemistry:  
For monitoring blood count, approximately 100 uL of blood was collected 
from the saphenous vein of live 14- to 17-week-old p53P72/P72 and p53R72/R72 mice 
before IR exposure. Mice were subjected to 6.135 Gy IR or left untreated, and 
blood sampling was repeated three days after exposure. Because other tissues 
were collected from mice on day seven following IR, for day seven blood counts 
and clinical chemistry, we sacrificed mice by CO2 inhalation and immediately 
removed approximately 500 uL of blood by cardiac puncture. 
For blood counts, blood was collected in sodium EDTA micro-tubes and 
counted using the Hemavet 950 hematology system (Drew Scientific, Miami 
Lakes, FL, USA). For clinical chemistry analysis, blood was collected in lithium 
heparin micro-tubes and analyzed using the Abaxis Vetscan VS2 clinical 
chemistry analyzer with Comprehensive Diagnostic Profile rotors #500-0038 
(Union City, CA, USA).  
 
Post IR spleen weight study:  
Mice were weighed prior to treatment and at sacrifice, and the spleen 
was weighed after formalin fixation.  
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Post-IR IHC analysis: 
Fourteen- to 17-week-old p53P72/P72 and p53R72/R72 mice were subjected to 
6 Gy IR (four-hour study) or 6.135 Gy IR (24-hour and seven-day study) or left 
untreated and sacrificed at the indicated time-points. Tissues were fixed in 10% 
buffered formalin, embedded in paraffin and sectioned routinely. IHC staining 
was used to detect cleaved lamin-A (Cell Signaling #2035, Danvers, MA, USA, 
1:50 dilution overnight at 4° C), γH2AX (Cell Signaling #2577, Danvers, MA, 
1:200 dilution, 2 hours at room temperature) and p53 (#SC-6243, Santa Cruz 
Biotechnology, CA, USA, 1:50 dilution one hour at room temperature). H & E 
staining was performed with Shandon Varistain Gemini automatic stainer 
(ThermoFischer Scientific, Waltham, MA, USA). Slides were digitized using a 
Scan Scope CS (Leica Biosystems, IL, USA) and analyzed with the manufacturer’s 
GENIE software (Spectrum version 10.2.2.2315). The standard DAB nuclear 
analysis program was modified to improve its ability to recognize 
immunopositive nuclei and the modified analysis algorithm was applied to 
selected tissues.  
 
Statistical testing: 
Statistical significance for most studies was determined with either a one-
way ANOVA followed by Tukey’s multiple comparison test, or a two-sided 
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independent t-test (as indicated on figure legends). For survival curves, a 
Kaplan–Meier estimate was generated and analyzed for statistical significance 
with the log-rank test employing Survival Package R (https://cran.r-project.org/). 
In all cases, tests with a p value of 0.05 or less were considered statistically 
significant. 
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3.3 Results  
 
3.3.1 The p53 R72P polymorphism in IR induced apoptosis in 
sensitive tissues 
Prior studies by our laboratory and others (using distinct but similar 
knock-in models) indicated that the p53 R72P polymorphism modulates 
apoptotic response to IR in the intestine and the thymus 112,116. To confirm this 
finding in the current model we conducted two sets of experiments using age 
and sex-matched mice that were at least three months of age.  
We treated FVB p53P72/P72 (P/P) and (R/R) female mice, housed together to 
synchronize estrous cycles, with 6 Gy IR, and sacrificed these mice at four hours 
following treatment. Untreated cage-mates were sacrificed as controls. 
Radiosensitive tissues were formalin fixed for IHC staining. At four hours, 
cleaved lamin-A positive cells, a marker of apoptosis147, increased in both 
genotypes in thymus, spleen, bone marrow and intestine when compared to 
tissues from untreated mice (Figure 3.1a ). The percentage of cleaved lamin-A 
positive cells was determined with digitized slides and histomorphometry image 
analysis software. At four hours, a significant difference in percent positive cells 
was present for all tissues when IR treated tissues were compared to untreated 
tissues (p<0.001 to p<0.05). A few differences were noted between genotypes, 
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the most prominent being apparently reduced apoptosis in IR treated p53P72/P72 
bone marrow when compared to IR treated p53R72/R72 bone marrow. However, in 
contrast to prior studies, there was lack of evidence for statistically significant 
differences between genotypes in any treatment group (Figure 3.1 b ).  
Next, we treated FVB p53P72/P72 (P/P) and p53R72/R72 (R/R) male mice with 
6.135 Gy IR, and sacrificed these mice at 24 hours following treatment. 
Untreated cage-mates were sacrificed as controls. At 24 hours following IR, IHC 
staining for cleaved lamin-A was increased compared to control tissues. There 
was also markedly diminished cellularity and more cellular debris in thymus, 
spleen, and bone marrow of IR treated mice compared to controls. These 
observations suggested ongoing and completed apoptosis. As in the four-hour 
study, at 24 hours there was no qualitative difference between genotypes for 
any treatment group (Figure 3.2a ) . The percentage of cleaved lamin-A 
positive cells was determined with digitized slides and histomorphometry image 
analysis software. At 24 hours there was an increased percentage of positive 
cells in IR treated tissues were compared to untreated tissues; however, a 
significant difference between treatment groups was only found in p53P72/P72 
spleen and intestine (p<0.001). Although the percent cleaved lamin-A positive 
nuclei in IR treated p53R72/R72 spleen and intestine was lower than the percent 
cleaved lamin-A positive nuclei in IR treated p53P72/P72 spleen and intestine, there 
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was lack of evidence for statistically significant differences between genotypes in 
any treatment group (Figure 3.2b ) .   Again, this is in contrast to prior studies.   
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Figure.3.1 Cleaved lamin–A staining in untreated and IR treated 
p53 R72 mice at four hours following IR. a) Representative images of 
cleaved lamin-A IHC in p53 R72P female, adult mice untreated or treated 
untreated or treated with 6 Gy IR at 4 hours and b) percent cleaved lamin-A 
positive cells in thymus, spleen, bone marrow and intestine in these mice.  
One-way ANOVA Tukey’s multiple comparisons test 
* p < 0.05, ** p <0.01, *** p <0.001 
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Figure 3.2 Cleaved lamin–A staining in untreated and IR treated 
p53 R72 mice at 24 hours following IR. a) Representative images of 
cleaved lamin-A IHC in male, adult p53 R72P mice untreated or treated with 
6.135 Gy IR at 24 hours b) percent cleaved lamin-A positive cells in thymus, 
spleen, bone marrow and intestine of these mice 
One-way ANOVA followed by Tukey’s multiple comparisons test 
 * p < 0.05, ** p <0.01, *** p <0.001 
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Although in prior studies we had noted no difference in p53 positive 
nuclei between IR treated or control p53P72/P72 and p53R72/R72 mice 112, we sought 
to confirm this was true in the current study. Western blot analysis of four 
biological replicates for each genotype in splenocytes from untreated and IR 
treated mice (four hours post IR) was carried out and quantified by densitometry. 
This study revealed significantly more p53 protein in splenocytes of IR treated 
p53P72/P72 (Figure 3.3 ).  
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Figure 3.3 p53 protein expression in IR treated and untreated 
p53 R72P splenocytes. p53 protein levels in splenocytes of adult male p53 
R72P mice untreated or exposed to 6.135 Gy IR and sacrificed at four hours after 
treatment a) western blot of four bioligical replicates of each 
genotype/treatment group (p53 knockout mouse spleenocytes used as negative 
control for antibody) b) densitometry of p53 protein expression normalized to 
GAPDH loading control  
two-sided independent t-test 
± refers to standard deviation 
* p<0.05 
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IHC staining for p53 was also performed on the tissues taken at four 
hours following IR and the control tissues for that treatment group. The 
percentage of p53 positive cells was determined with digitized slides and 
histomorphometry image analysis software. Unlike in prior studies from our lab 
112, and in line with the western blot results in the current study, there appeared 
to be some increased p53 expression in IR treated p53P72/P72 mouse thymus, 
spleen and intestine when compared to and p53R72/R72 mouse tissues (Figure 
3.4 ) although these differences were not significant. However, we cannot rule 
out that these differences may be due to increased affinity of the antibodies 
employed to proline variant p53. In support of this possibility, we have noted 
that at least one commercially available antibody could not recognize the R 
variant p53 at all (Figure 3.5)  
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Figure 3.4 Quantification of IHC staining for p53 protein in 
untreated and IR treated p53 R72P mouse tissues. Percent p53 
positive nuclei in adult p53 R72P female mice untreated or treated with 6 Gy IR 
at 4 hours in a) thymus, b) spleen, c) bone marrow and d) intestine  
two-sided independent t-test 
 * p < 0.05, ** p <0.01 
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Figure 3.5 A commercially available antibody fails to recognize 
p53 R72P R variant. p53 R72P mouse adult fibroblasts (MAFs) were treated 
with 10 Gy IR and lysed at four, 18 or 24 hours following IR. Lysates were probed 
with a) anti-p53 antibody (Vector CM5) or with b) anti-phopho-p53 antibody 
(Ser 15). p53 WT and p53 KO MAFs were used as positive and negative 
controls, respectively. 
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3.3.2  The p53 R72P polymorphism in the transcriptional 
regulation of p53 target genes following IR: 
The p53 R72P polymorphism may influence p53 target gene expression 
upon exposure to genotoxic agents93,95,112,115,116. To determine whether p53 
target gene expression would differ between p53 R72P polymorphic variants 
following IR in this project, I extracted RNA from thymocytes of adult, male 
p53P72/P72 and p53R72/R72 mice four hours after exposure to 6.135 Gy IR and from 
the thymocytes of control mice. Quantitative PCR was performed to measure the 
expression levels of common p53 target genes. Expression of p53 was also 
measured, in light of the above noted increased expression of p53 protein in 
p53P72/P72 mouse tissues as compared to p53R72/R72 mouse tissue (Figure 3.4 
and Figure 3.5 ). Furthermore, some studies have shown p53 is involved in 
regulating its own transcription, and such transcription may be upregulated by 
exposure to genotoxic agents44,148. 
As expected, a significant increase was seen in gene expression of p21, 
Bax, Noxa and Puma in thymocytes from IR treated mice when compared to 
thymocytes from untreated mice. For these genes, this was true for both 
genotypes. For Mdm2, a statistically significant increase in IR treated thymocytes 
compared to untreated thymocytes was only noted in thymocytes from p53P72/P72 
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mice. It also appeared that Mdm2 was not induced in thymocytes from IR 
treated p53R72/R72 mice, although the difference between Mdm2 expression in IR 
treated thymocytes in p53P72/P72 compared to p53R72/R72 mice was not significant.  
In contrast to earlier studies112,115, there were no differences in gene expression 
of p21, Bax, Noxa, Perp and Puma in thymocytes from either IR-treated or 
untreated p53P72/P72 and p53R72/R72 mice. IR treatment significantly reduced p53 
gene expression in thymocytes, but there were no differences between 
thymocytes from p53P72/P72 and p53R72/R72 mice (Figure 3.6 ). This is in contrast to 
prior studies suggesting that genotoxic insult increases p53 transcription44. 
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Figure 3.6 p53 target gene expression in p53 R72P mice 
untreated or treated with IR. p53 target gene expression in thymocytes 
of adult, male p53 R72P mice untreated or treated with 6.135 Gy IR and 
sacrificed at four hours following treatment, expressed as fold change over 
untreated P/P mice: a) p53 b) p21 c) Mdm2 d) Noxa e) Bax f) Puma and g) 
Perp  
One-way ANOVA followed by Tukey’s multiple comparisons test 
± refers to standard deviation 
 ns=not significant  
* p < 0.05, ** p <0.01, *** p <0.001  
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3.3.3  The p53 R72P polymorphism in DNA damage repair.  
Studies in cell culture have shown that cells expressing the proline variant 
of p53 have improved ability to repair DNA after DNA damage 94. We sought to 
test whether the p53 R72P polymorphism would alter DNA double strand break 
(DSB) resolution. To test this, IHC staining for phosphorylated histone H2AX 
(γH2AX) - a marker of DNA DSBs 149 - was performed on thymus and spleen from 
IR treated and untreated p53P72/P72 and p53R72/R72 mice. At four hours and 24 
hours following IR there was increased staining for γH2AX when compared to 
untreated mice. There was less γH2AX staining in tissues of mice sacrificed at 24 
hours following IR when compared to mice sacrificed at 4 hours following IR, but 
also decreased cellularity at 24 hours. This implies that there was irreparable 
DNA damage that led to apoptosis and perhaps DNA DSB resolution with 
γH2AX clearance. There were no obvious differences between γH2AX staining in 
tissues p53P72/P72 and p53R72/R72 mice at either time point. (Figure 3.7 ). We used 
digitized slides and histomorphometry image analysis software to quantify the 
percent of γH2AX nuclei. IR treated mice displayed significantly higher 
percentages of γH2AX stained cells when compared to untreated mice 
(p<0.0001 to p<0.01). However, there were no differences in the percent of  
γH2AX positive cells between p53P72/P72 and p53R72/R72 mice (Figure 3.8 ). 
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Figure 3.7 IHC staining for γH2AX in p53 R72P mice untreated or 
treated with IR. Representative images of γH2AX IHC in adult p53 R72P 
mice: a) females untreated or treated with 6 Gy IR at 4 hours b) males untreated 
or treated with 6.135 Gy IR at 24 hours 
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Figure 3.8 Quantification of γH2AX staining in p53 R72P mice 
untreated or treated with IR. Percent γH2AX positive nuclei in adult p53 
R72P female mice untreated or treated with 6 Gy IR at 4 hours in a) thymus c) 
spleen; p53 R72P male mice untreated or treated with 6.135 Gy at 24 hours in 
b) thymus d) spleen  
One-way ANOVA followed by Tukey’s multiple comparisons test 
* p < 0.05, ** p <0.01, *** p <0.001 
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3.3.4  The p53 R72P polymorphism in tissue homeostasis 
following IR 
To examine how the p53 R72P polymorphism impacts the hematopoietic 
system during IR therapy, blood counts and blood clinical chemistry analysis 
were performed on adult p53P72/P72 and p53R72/R72 mice. Unlike our doxorubicin 
studies, in IR studies, white blood cell, neutrophil and lymphocyte counts for 
both genotypes decreased significantly at three and seven days following 
treatment. However, no statistically significant differences were noted between 
p53P72/P72 and p53R72/R72 mice in the IR treated or untreated groups (Figure 3.9 ). 
Blood clinical chemistry analysis was also performed on adult male p53P72/P72 and 
p53R72/R72 mice treated with IR or untreated. However, few statistically significant 
changes were noted, even between treatment groups, suggesting this was a 
poor measure of the physiological effects of this treatment regimen, at least at 
seven days following IR (Table 3.1 ).  
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Figure 3.9 Hematology in p53 R72P mice untreated or treated 
with IR. Hematology in adult p53 R72P mice untreated or treated with 6.135 
Gy IR at 0, 3 and 7 days: a) white blood cell counts, b) neutrophil counts, c) 
lymphocyte counts  
One-way ANOVA followed by Tukey’s multiple comparisons test 
* p < 0.05, ** p <0.01, *** p <0.001 
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Genotype IR*treatment Albumin
Alkaline*
phosphatase
Alanine*
aminotransferase
Amylase Bilirubin*
Blood*urea*
nitrogen
Calcium Phosphorous Creatine* Glucose* Sodium Potasium** Total*protein Globulin
P/P N 3.7 65.0 763.0 1700.0 0.4 28.0 11.1 12.6 0.2 213.0 156.0 8.5 6.3 2.6
P/P N 3.8 21.0 213.0 1291.0 ND 21.0 11.3 14.4 0.3 308.0 154.0 ND 5.7 1.9
P/P N 3.8 88.0 39.0 1218.0 0.4 31.0 10.5 9.3 0.3 189.0 155.0 8.5 6.0 2.2
Average 3.8 58.0 338.3 1403.0 0.4 26.7 11.0 12.1 0.3 236.7 155.0 8.5 6.0 2.2
P/P Y 3.8 63.0 43.0 1287.0 0.4 21.0 10.1 10.8 0.4 184.0 155.0 8.5 5.8 2.0
P/P Y 4.1 83.0 100.0 1071.0 0.3 20.0 11.2 12.2 0.3 337.0 154.0 8.5 6.1 2.0
P/P Y 4.0 34.0 440.0 1085.0 0.3 22.0 10.4 13.6 0.3 193.0 193.0 ND 5.6 1.5
Average 4.0 60.0 194.3 1147.7 0.3 21.0 10.6 12.2 0.3 238.0 167.3 8.5 5.8 1.8
R/R N 3.5 73.0 40.0 1382.0 0.3 22.0 9.7 9.9 0.2 184.0 154.0 8.5 5.6 2.1
R/R N 3.7 50.0 34.0 1259.0 0.3 27.0 10.7 10.7 0.4 193.0 159.0 8.5 5.7 2.0
R/R N 3.8 42.0 1011.0 1178.0 0.3 23.0 11.1 12.2 0.5 293.0 157.0 8.5 6.1 2.3
R/R N 3.8 66.0 12.0 1258.0 0.3 29.0 8.9 11.1 0.2 273.0 156.0 12.0 6.2 2.3
Average 3.7 57.8 274.3 1269.3 0.3 25.3 10.1 11.0 0.3 235.8 156.5 9.4 5.9 2.2
R/R Y 3.9 76.0 44.0 1213.0 0.4 16.0 10.4 10.4 0.2 229.0 154.0 8.5 5.8 2.0
R/R Y 4.2 71.0 113.0 1275.0 0.4 25.0 10.7 11.0 0.5 174.0 155.0 8.2 6.0 1.7
R/R Y 4.0 59.0 48.0 1231.0 0.4 24.0 10.3 11.1 0.2 158.0 157.0 8.2 6.0 2.0
Average 4.0 68.7 68.3 1239.7 0.4 21.7 10.5 10.8 0.3 187.0 155.3 8.3 5.9 1.9
0.139 0.939 0.604 0.226 NA 0.192 0.386 0.957 NA 0.984 0.438 NA 0.503 0.205
0.039 0.267 0.464 0.554 0.000 0.349 0.520 0.801 NA 0.223 0.432 NA 0.846 0.092
0.621 0.613 0.417 0.317 0.184 0.838 0.797 0.228 NA 0.421 0.449 NA 0.579 0.752
0.440 0.991 0.853 0.470 NA 0.702 0.188 0.536 NA 0.985 0.269 NA 0.681 0.808
p"value*TLtest*P/P*IR*to*untreated
p"value*TLtest*R/R*IR*to*untreated
p"value"TLTest*P/P*to*R/R*IR
p *value*TLTest*P/P*to*R/R*untreated
 
 
 
 
 
 
 
 
 
 
 
Table 3.1 Clinical parameters in p53 R72P mice untreated of 
treated with IR. Blood clinical chemistry in adult male p53 R72P mice 
untreated or treated with 6.135 Gy IR at 7 days. * Creatine values quantified as 
<0.2 are included as 0.2, and ** Potassium values quantified as >8.5 and >12.0 
are included as 8.5 and 12 on this table for general reference, ND= no data, 
NA=not applicable, p values from two sided independent t-test 
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Qualitative differences between IR sensitive tissues from p53P72/P72 and 
p53R72/R72 mice exposed to IR at seven days following treatment and from 
untreated mice were assessed by histopathology to determine if there were 
differences in tissue pathology and recovery. At this time point, there was still 
greatly reduced cellularity in the thymus, spleen and bone marrow of IR treated 
mice compared to controls (Figure 3.10 ). There was a slight increase in 
intestinal cellularity in IR treated mice, suggesting early recovery from treatment. 
Nevertheless, there was no notable difference between p53P72/P72 and p53R72/R72 
IR-treated or control tissues (Table 3.2 ). The effect of IR on cellularity of the IR 
sensitive tissues was further evidenced by a marked decrease in the weight of 
fixed spleen as a percentage of body weight in IR treated mice at seven days 
following treatment, as compared to untreated mice in both genotypes. 
However, there was no difference in the weight of fixed spleen as a percent of 
body weight between p53P72/P72 and p53R72/R72 mice at either time point or in each 
treatment group (Figure 3.11 ). 
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Figure 3.10 Histopathology in p53 R72P mice untreated or 
treated with IR. H & E staining showing representative histopathology in 
adult male p53 R72P mice untreated or treated with 6.135 Gy IR at seven days 
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Table 3.2 Summary of histopathological report of p53 R72P mice 
untreated or treated with IR. Histopathological changes in adult male p53 
R72P mice untreated or treated with 6.135 Gy IR at 7 days. NP: Not present. 
 
Genotype Treatment,group Thymus,Cellularity Spleen,Cellularity
Bone,Marrow,
Cellularity,
Intestinal,Crypt,
Hyperplasia
P/P Untreated Marked Marked Marked None
P/P Untreated Marked Marked Marked None
P/P Untreated Marked Marked Marked Minimal
P/P IR3Treated Minimal Mild Minimal Mild
P/P IR3Treated Minimal Mild Mild Minimal
P/P IR3Treated Mild Mild Minimal Minimal
R/R Untreated Marked Marked Marked None
R/R Untreated Moderate Marked Marked None
R/R Untreated Marked Marked Marked None
R/R IR3Treated Minimal Mild Minimal Minimal
R/R IR3Treated Minimal Mild Minimal Minimal
R/R IR3Treated NP Mild Minimal Minimal
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Figure 3.11 Spleen weights in p53 R72P mice untreated or 
treated with IR. The effects of IR on fixed spleen weight as a percent of 
body weight in adult p53 R72P mice untreated or treated with 6.135 Gy IR at 7 
days.  
One way ANOVA followed by Tukey’s multiple comparisons test 
 *** p <0.001 
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3.3.5  The p53 R72P polymorphism in long-term survival and 
weight loss following IR 
 
To determine whether the R72P polymorphism affected mouse survival, 
FVB p53P72/P72 and p53R72/R72 mice were treated with 6.135 Gy IR and followed for 
28 days or until they became moribund, at which point they were sacrificed. A 
mouse was judged to be moribund if it showed hunched posture, lethargy, 
greater than 20 percent weight loss, anorexia and rapid or labored breathing. To 
ensure that morbidity was not a result of opportunistic infection, mice were 
housed in sterile caging and treated with prophylactic antibiotics in their 
drinking water. Most mice became moribund before 25 days, and the majority 
were sacrificed between 10-20 days following treatment. All mice in this study 
were within five days of 15 weeks old and at least 20 male and 20 female mice 
of each genotype were used. A log-rank test was used to analyze survival curves, 
and the results showed that the p53 R72P polymorphism failed to modulate 
survival in adult male mice, female mice, or the both sexes as a combined group 
(Figure 3.12 ).  
Since adverse effects of IR include gastrointestinal distress that may affect 
weight, mice in this study were weighed at day zero and day seven following IR 
treatment. Although body weight decreased for both genotypes and sexes 
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between five and 10 percent from day zero and day seven, and this change in 
weight was not significant and there was no significant difference in weight 
between p53P72/P72 and p53R72/R72 mice at either time-point for either sex (Figure 
3.13 ) .   
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  a	   	   	   	   	  	  b	   	   	   	   	  	  c	  
  
 
 
Figure 3.12 28-day survival in p53 R72P mice treated with IR. 
Kaplan-Meier survival curves for adult p53 R72P mice treated with 6.135 Gy IR 
and followed for 28 days: a) males (P/P males n=20, R/R males n=20, log rank 
test: ns) b) females (P/P females n=20, R/R females n=21, log rank test: ns) and 
c) both sexes combined (P/P n=40, R/R n=41, log-rank test: ns)  
ns: not significant 
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Figure 3.13 Weights in p53 R72P mice untreated or treated with IR. No 
significant change in weight of adult p53 R72P treated with 6.135 Gy IR at zero 
and seven days a) male mice b) female mice  
One way ANOVA followed by Tukey’s multiple comparisons test 
ns= not significant 
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3.4  Discussion  
  In this Chapter, I describe using p53 R72P mice to examine the 
effects of the R72P polymorphism on tissue damage, tissue recovery and long 
term survival following high dose IR treatment. There appeared to be some 
minor differences in levels of p53 protein in some tissues when mice were 
exposed to IR, with the proline variant generally showing higher levels of p53.  
This minor difference did not seem to affect outcomes of IR exposure 
either at the cellular or physiological level. This is evidenced by several key 
results: 1) Expression of p53 target genes in IR-treated and untreated mouse 
thymocytes was very similar between p53 R72P genotypes. 2) Quantification of 
IHC staining suggested that the p53 R72P polymorphism did not affect 
apoptosis in several radiosensitive tissues following IR exposure either at four or 
24 hours. 3) There were no differences in nuclear γ-H2AX IHC staining at either 
four or 24 hours following IR treatment, suggesting no difference in the timing 
or vigor of DNA damage response or repair between p53P72/P72 and p53R72/R72 
mice. 4) Thymus, spleen and bone marrow showed highly decreased cellularity 
at seven days following IR when compared to untreated tissue, but there were 
no apparent differences between p53P72/P72 and p53R72/R72 mice. These data 
suggest that neither immediate pathological response to IR nor short-term 
recovery are affected by the polymorphism. 5) Leukocyte numbers were 
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unaffected by the p53 R72P polymorphism at three and seven days following IR, 
with equivalent leukopenia in both genotypes. These data suggest that 
myelosuppression by IR is also equivalent between genotypes. 6) In a 28-day 
survival study, no difference was seen in survival between p53P72/P72 and p53R72/R72 
mice exposed to high-dose IR. These data suggest that recovery from adverse 
effects of IR, such as bone marrow suppression and intestinal epithelial damage, 
were not affected by the polymorphism.  
Previously, our laboratory and others found different levels of apoptosis 
when p53 R72P humanized mice were exposed to IR. For example, there was 
more nuclear IHC staining for markers of apoptosis in p53R72/R72 mouse intestine 
as compared to p53P72/P72 mouse intestine 112,116. Furthermore, there was 
increased nuclear staining for apoptotic markers in p53P72/P72 mouse thymus 
compared to p53R72/R72 mouse thymus 115. We did not find such differences in 
nuclear staining for apoptosis in the current project. As one study suggested 
that there were differences between p53 R72P cell lines in DNA response and 
repair following genotoxic insult 94, we tested this in mice by IHC staining for 
γH2AX at four and 24 hours post IR in spleen and thymus. Although there was a 
large difference in γH2AX in staining between treated and untreated mouse 
tissue, there was no difference between p53P72/P72 and p53R72/R72 in either 
treatment group.  
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Data from the current project do not support a role for the p53 R72P 
polymorphism in moderating the effects of high-dose TBI. However, this project 
did not include studying side effects of targeted IR treatment, or the adverse 
effects of fractionated IR dosing, so those may need to be investigated. Also, as 
this study focuses on the effect of the p53 R72P polymorphism as a single 
genetic variable, the effects of genetic interactions between this SNP and others 
in modifying IR-induced side effects cannot be excluded. Continued study of the 
p53 R72P polymorphism may be merited in these contexts.  
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Chapter 4: 
Summary and Future Directions 
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There are over 80 million human SNPs documented in the human 
genome111, so singling out the adverse effects of one SNP on cancer therapies 
can be challenging. Epidemiological studies of individual SNPs cannot always 
account for other genetic variances, environmental differences and differences 
in cancer treatments. Cell culture studies cannot often predict 
systemic/physiological differences in cancer therapy tolerance. We postulated 
that mouse models of SNPs could serve to bolster our understanding of 
pharmacogenomics and radiogenomics as they pertain to the adverse effects of 
genotoxic cancer therapies.  
Investigators have extensively utilized genetically modified mice to 
understand the functions, regulation and cancer phenotypes of WT and mutant 
p53. These mouse models include those in which a portion of a mouse gene is 
replaced by the orthologous human section109, such as the mice used in this 
dissertation project. Other such “genomically humanized mice” have been 
created to improve xenogeneic transplantation, to model non-cancer human 
diseases and to produce mice with more human-like cytochrome P450 activity 
for use in predicting drug-drug interactions in humans150. Genomically 
humanized mice have also been used to determine how human SNPs in p53 
pathway genes affect tumor latency and spectrum, and the molecular 
mechanisms involved. For example, Lozano et al. generated KI models of a 
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common human SNP in the Mdm2 gene (G309T), which is not conserved in 
mice. Employing these models, they demonstrated that mice with the G variant 
express lower levels of Mdm2, and decreased apoptosis in some tissues as 
compared to mice with the T variant. Furthermore, in mice heterozygous for a 
hot-spot p53 mutation, mice with the G allele succumbed to tumors sooner and 
displayed an altered tumor spectrum when compared to mice with the T 
allele110.  
The study of SNPs using genomically humanized mouse models in 
pharmacogenomics has also been established. Such models have been used to 
study how a human SNP in the opioid-receptor-μ-1 gene modifies heroin 
addiction151. Additionally, they have been used to model a human SNP in the 
brain-derived-neurotrophic-factor gene which is associated with decreased 
hippocampal size and decreased memory in humans. Mice with one variant of 
this human SNP also showed an anxiety phenotype that has not been confirmed 
in humans with the same SNP variant. This allowed the researchers to test how 
the SNP affected the efficacy of fluoxetine, which is used to treat anxiety.152  
In spite of their utility in other fields of pharmacogenomics, genomically 
humanized mouse models of SNPs have not been used to characterize how 
human SNPs modulate side effects of therapeutic doses of chemotherapeutics. 
We also noted that no radiogenomic studies using genomically humanized 
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mouse models of SNPs have been published. Therefore, we sought to establish 
the utility of such models in the fields of pharmacogenomics and radiogenomics 
by using our mouse models of the p53 R72P polymorphism to characterize how 
this human SNP affects doxorubicin tolerance and to show the adverse effects of 
radiation therapy.  
We found that a therapeutic dose of doxorubicin induced only minor 
cellular and systemic changes in FVB mice. These changes were, for the most 
part, not robust enough to be effectively quantified or validated. We then tested 
WT FVB at escalating doses of doxorubicin and found very little evidence of 
quantifiable adverse effects even at the highest doses. Whether FVB mice are 
particularly insensitive to doxorubicin compared to other mouse strains is not 
known. It would be advisable for any researcher considering a similar study to 
first test for measurable differences in systemic effects of doxorubicin in the WT 
mice of the mouse strain they intend to use prior to using genetically modified 
mouse models.  
We do not know if other commonly used genotoxic chemotherapies, 
alone or in combination, would induce measurable differences in adverse effects 
or gene expression profiles in our mouse models of the p53 R72P 
polymorphism. Epidemiological studies have shown increased febrile 
neutropenia in patients homozygous for the proline allele in response to 5-
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florourical(5-FU)/epirubicin/cyclophosphamide treatments and increased 
neutropenia in response to etoposide/cisplatin treatment, compared to patients 
hetero- or homozygous for the arginine variant 100,101. Future studies could use 
these chemotherapy combinations in p53 R72P polymorphic mice to determine 
if their response would model the epidemiological data. If they were good 
models, p53 R72P mice could serve as an in vivo pre-clinical proxy to test how 
changes in these regimens could reduce systemic effects in some patients.  
As compared to the doxorubicin study, using our p53 R72P mouse 
models in IR studies provided much more robust differences between treatment 
and control groups. However, in contrast to earlier studies with IR, there was 
little to no difference between proline and arginine variants. Expression of 
common p53 target genes in thymocytes from untreated and IR treated mice 
was not affected by the p53 R72P polymorphism. Although there may have 
been slightly increased p53 protein levels in tissues from p53P72/P72 mice when 
compared to tissues from p53R72/R72 mice, these differences did not lead to 
changes at a physiological level. Neither early changes in cellular markers of 
apoptosis and DNA damage, nor short-term changes in tissue damage and 
recovery were noted between genotypes. Survival from high-dose IR to 28 days 
also did not differ between genotypes, suggesting similar long-term recovery in 
p53 R72P variants. Although no other published reports have tested systemic 
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effects and DNA damage markers in mice following IR treatment using p53 R72P 
polymorphic mouse models, several studies have tested tissue-specific 
differences in apoptosis and transcriptional activation of p53 targets in response 
to IR. As previously described in earlier studies, p53 R72P mouse models in our 
laboratory and the Murphy laboratory had shown some tissue specific 
differences in apoptosis and between genotypes and gene expression changes 
consistent with these changes112,115. 
In this dissertation project I saw few such differences. There are several 
possible reasons for this discrepancy. Although the age of the mice used in the 
Murphy laboratory experiments is not documented, in prior studies from our 
laboratory, young mice approximately eight weeks of age had been used. Early 
studies of the pathology of IR injury in mice have shown that radio-resistance 
follows a u-shaped pattern of high neonatal resistance, decreased resistance 
during maturation and a return to higher resistance with maturity118. Therefore, 
individual developmental differences between mice still reaching maturity could 
have accounted for changes in response to IR noted in our original studies.  
Technological advances could also account for some differences. In prior 
studies, IHC quantification was performed with light microscope and apoptotic 
cells were counted manually by observation from small linear sections of tissues. 
In this study, slides were digitized and nuclear staining was quantified by 
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computer algorithm. This allowed us to gather information about much larger 
(and therefore more representative) sections of tissue and eliminated any 
unintentional bias associated with manual counts.  
As previously discussed, background strain can influence gene expression 
patterns and radio-sensitivity120-122. In the case of reports from our laboratory, 
prior studies had been unwittingly performed on mice with mixed background 
strains. Therefore, it is possible that the differences we noted were artifacts of 
background strain and not the polymorphism. We do not know to what extent 
the Murphy laboratory has characterized the genetic background of mice in their 
reports, but they used mice backcrossed into a C57BL/6 background. It is 
possible that this background strain has subtle genetic differences in p53 target 
genes that modulated the interaction of R and P humanized p53 with important 
transcriptional targets or nuclear and cytoplasmic proteins. Furthermore, 
different targeting vectors were used in the creation of p53 R72P mice between 
the two laboratories. The vector used in our laboratory replaced p53 mouse 
exon four with human exon four coding for either the 72R or 72P variant. 
However, in the Murphy laboratory model vectors, several exons of mouse p53 
were replaced with human R72P coding variant exons. The effect of any of these 
differences could result in genetic interactions and protein/protein interactions 
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that enhanced p53 R72P polymorphism-driven differences in one model and 
muted them in another.  
In this dissertation project I did not find significant differences in 
inflammation associated gene expression in the liver or thymus of mice exposed 
to doxorubicin. I did not test inflammatory gene expression in response to IR. 
However, as previously described, the p53 R72P polymorphism has been shown 
to modify inflammation in some tissues as shown by differential gene 
expression, tissue changes as well as systemic responses to genotoxic stimuli, 
tumor growth and endotoxin injection. One proposed mechanism for these 
differences is increased binding of the NF-κB subunit p65 RelA with the proline 
variant of p53, leading to increased upregulation of inflammatory genes115,117.  
Considering this, it may be important to use p53 R72P polymorphic 
mouse models to test the how the polymorphism modifies both the adverse 
effects and the efficacy of immunological-based cancer therapies. For example, 
rituximab, an anti-CD-20 antibody used to treat B-cell lymphomas and leukemia, 
can cause severe cytokine release syndrome (CRS) with symptoms such as fever 
and hypotension that have been fatal153,154. The mode of actions for its efficacy 
as a cancer treatment are mediated in part due to the inhibition NF-κB signaling 
and increased Fas receptor/ligand signaling155. How these signaling pathways 
are involved in CRS is not clear, although NF-κB signaling is a well-known 
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inducer of cytokine activity and pro-survival signaling156, and Fas signaling is 
generally known to be immunosuppressive via its activity in inducing caspase-8 
mediated apoptosis in immune cells157. Interestingly, the Fas receptor is a long-
accepted p53 transcription target158, but whether or not the p53 R72P 
polymorphism modulates Fas expression is unknown. Therefore, many avenues 
of study regarding the role of the p53 R72P polymorphism in CRS could be 
explored. This could be technically challenging as these anti-tumor-antibodies 
are designed for use in humans and do not elicit the same effects in mice, so our 
current models of the polymorphism may not be useful. However, humanizing 
severe combined immunodeficiency (SCID) immune deficient mice with human 
peripheral blood mononuclear cells (PBMCs) can be used to model CRS in the 
context of antibody based therapies159. Therefore, it’s possible to imagine using 
p53 72R and 72P PBMCs in SCID mice in a similar manner to test how the 
polymorphism affects CRS, and, if it does, examining the roles of NF-κB and Fas 
signaling in any such differences. However, to date no 
epidemiological/pharmacogenomic studies have addressed whether the p53 
R72P polymorphism (or any polymorphism of any gene) specifically affects CRS, 
so mouse model studies may be premature.  
There are other polymorphisms in the p53 gene and these may affect 
responses to cancer therapy and side effects of cancer therapy. For example, 
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another humanized mouse model from the Murphy laboratory of the p53 
Pro47Ser polymorphism found that MEFs from p53Ser47/Ser47 mice were much less 
sensitive to cisplatin than MEFs from p53Pro47/Pro47 mice. However, when these 
MEFs were oncogene transformed, the reverse was true: p53Ser47/Ser47 MEFs were 
more sensitive 160. In another report, the Murphy laboratory found that this 
difference in sensitivity to cisplatin was caused by a combination of decreased 
apoptosis and ferroptosis in p53Ser47/Ser47 MEFs compared to p53Pro47/Pro47 MEFs. 
They confirmed the decreased sensitivity of p53Ser47/Ser47 MEFs to cisplatin and 
ferroptosis inducing agents in human p53Ser47/Ser47 lymphoid cell lines161. Although 
they did not use their mice to model side-effects per se, these data suggest that 
polymorphisms can differently modulate sensitivity to genotoxic insult in healthy 
and transformed tissue and underscore the utility of mouse models in predicting 
such differences in human tissues.  
The evidence in this dissertation does not support a major role for the 
p53 R72P polymorphism in moderating adverse effects of genotoxic therapy. 
However, pharmaco- and radiogenomics fields continue to elucidate the roles of 
subtle genetic changes in both tumor response and systemic effects of cancer 
therapies. The relevance and timeliness of radiogenomic studies, especially, is 
emphasized by a recent news article in Science addressing the need for 
increased study and novel methodology in this field162. Considering this, current 
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and improved humanized mouse models of SNPs may be increasingly important 
in bridging the gap between cell culture and epidemiological studies. This 
dissertation project shows the feasibility of using humanized mouse models to 
test the impact of a polymorphism on adverse effects of cancer therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   114 
Bibliography: 
 
1 Linzer, D. I. & Levine, A. J. Characterization of a 54K dalton cellular SV40 
tumor antigen present in SV40-transformed cells and uninfected 
embryonal carcinoma cells. Cell 17, 43-52 (1979). 
2 Kress, M., May, E., Cassingena, R. & May, P. Simian virus 40-transformed 
cells express new species of proteins precipitable by anti-simian virus 40 
tumor serum. Journal of virology 31, 472-483 (1979). 
3 Lane, D. P. & Crawford, L. V. T antigen is bound to a host protein in 
SV40-transformed cells. Nature 278, 261-263 (1979). 
4 DeLeo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W. & Old, L. J. 
Detection of a transformation-related antigen in chemically induced 
sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U 
S A 76, 2420-2424 (1979). 
5 Crawford, L. V., Pim, D. C., Gurney, E. G., Goodfellow, P. & Taylor-
Papadimitriou, J. Detection of a common feature in several human tumor 
cell lines--a 53,000-dalton protein. Proc Natl Acad Sci U S A 78, 41-45 
(1981). 
	  	   115 
6 Crawford, L. V., Pim, D. C. & Bulbrook, R. D. Detection of antibodies 
against the cellular protein p53 in sera from patients with breast cancer. 
Int J Cancer 30, 403-408 (1982). 
7 Crawford, L. V., Pim, D. C. & Lamb, P. The cellular protein p53 in human 
tumours. Mol Biol Med 2, 261-272 (1984). 
8 Mercer, W. E., Nelson, D., DeLeo, A. B., Old, L. J. & Baserga, R. 
Microinjection of monoclonal antibody to protein p53 inhibits serum-
induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A 79, 6309-
6312 (1982). 
9 Jenkins, J. R., Rudge, K. & Currie, G. A. Cellular immortalization by a 
cDNA clone encoding the transformation-associated phosphoprotein 
p53. Nature 312, 651-654 (1984). 
10 Eliyahu, D., Raz, A., Gruss, P., Givol, D. & Oren, M. Participation of p53 
cellular tumour antigen in transformation of normal embryonic cells. 
Nature 312, 646-649 (1984). 
11 Parada, L. F., Land, H., Weinberg, R. A., Wolf, D. & Rotter, V. 
Cooperation between gene encoding p53 tumour antigen and ras in 
cellular transformation. Nature 312, 649-651 (1984). 
12 Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., 
Romano, J. W. & Ullrich, S. J. Negative growth regulation in a 
	  	   116 
glioblastoma tumor cell line that conditionally expresses human wild-type 
p53. Proc Natl Acad Sci U S A 87, 6166-6170 (1990). 
13 Hinds, P., Finlay, C. & Levine, A. J. Mutation is required to activate the 
p53 gene for cooperation with the ras oncogene and transformation. 
Journal of virology 63, 739-746 (1989). 
14 Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. & Vogelstein, B. 
Suppression of human colorectal carcinoma cell growth by wild-type p53. 
Science 249, 912-915 (1990). 
15 Lane, D. P. & Benchimol, S. p53: oncogene or anti-oncogene? Genes Dev 
4, 1-8 (1990). 
16 Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. 
W. Participation of p53 protein in the cellular response to DNA damage. 
Cancer Res 51, 6304-6311 (1991). 
17 el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., 
Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. & Vogelstein, B. WAF1, 
a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993). 
18 el-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., 
Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., 
Wang, Y. & et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and 
apoptosis. Cancer Res 54, 1169-1174 (1994). 
	  	   117 
19 Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. 
V., Plunkett, B. S., Vogelstein, B. & Fornace, A. J., Jr. A mammalian cell 
cycle checkpoint pathway utilizing p53 and GADD45 is defective in 
ataxia-telangiectasia. Cell 71, 587-597 (1992). 
20 Zhan, Q., Carrier, F. & Fornace, A. J., Jr. Induction of cellular p53 activity 
by DNA-damaging agents and growth arrest. Mol Cell Biol 13, 4242-
4250 (1993). 
21 Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. & Oren, 
M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is 
inhibited by interleukin-6. Nature 352, 345-347, doi:10.1038/352345a0 
(1991). 
22 Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B. & Costa, J. Induction 
of apoptosis by wild-type p53 in a human colon tumor-derived cell line. 
Proc Natl Acad Sci U S A 89, 4495-4499 (1992). 
23 Miyashita, T. & Reed, J. C. Tumor suppressor p53 is a direct 
transcriptional activator of the human bax gene. Cell 80, 293-299 (1995). 
24 Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is 
induced by p53. Mol Cell 7, 683-694 (2001). 
25 Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., 
Tokino, T., Taniguchi, T. & Tanaka, N. Noxa, a BH3-only member of the 
	  	   118 
Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 
288, 1053-1058 (2000). 
26 Vaseva, A. V. & Moll, U. M. The mitochondrial p53 pathway. Biochim 
Biophys Acta 1787, 414-420, doi:10.1016/j.bbabio.2008.10.005 (2009). 
27 Riley, T., Sontag, E., Chen, P. & Levine, A. Transcriptional control of 
human p53-regulated genes. Nat Rev Mol Cell Biol 9, 402-412, 
doi:10.1038/nrm2395 (2008). 
28 Kenzelmann Broz, D., Spano Mello, S., Bieging, K. T., Jiang, D., Dusek, R. 
L., Brady, C. A., Sidow, A. & Attardi, L. D. Global genomic profiling 
reveals an extensive p53-regulated autophagy program contributing to 
key p53 responses. Genes Dev 27, 1016-1031, 
doi:10.1101/gad.212282.112 (2013). 
29 Vousden, K. H. & Ryan, K. M. p53 and metabolism. Nat Rev Cancer 9, 
691-700, doi:10.1038/nrc2715 (2009). 
30 Vousden, K. H. & Prives, C. Blinded by the Light: The Growing 
Complexity of p53. Cell 137, 413-431, doi:10.1016/j.cell.2009.04.037 
(2009). 
31 Sengupta, S. & Harris, C. C. p53: traffic cop at the crossroads of DNA 
repair and recombination. Nat Rev Mol Cell Biol 6, 44-55, 
doi:10.1038/nrm1546 (2005). 
	  	   119 
32 Menon, V. & Povirk, L. Involvement of p53 in the repair of DNA double 
strand breaks: multifaceted Roles of p53 in homologous recombination 
repair (HRR) and non-homologous end joining (NHEJ). Subcell Biochem 
85, 321-336, doi:10.1007/978-94-017-9211-0_17 (2014). 
33 Maltzman, W. & Czyzyk, L. UV irradiation stimulates levels of p53 cellular 
tumor antigen in nontransformed mouse cells. Mol Cell Biol 4, 1689-1694 
(1984). 
34 Juven, T., Barak, Y., Zauberman, A., George, D. L. & Oren, M. Wild type 
p53 can mediate sequence-specific transactivation of an internal 
promoter within the mdm2 gene. Oncogene 8, 3411-3416 (1993). 
35 Zauberman, A., Barak, Y., Ragimov, N., Levy, N. & Oren, M. Sequence-
specific DNA binding by p53: identification of target sites and lack of 
binding to p53 - MDM2 complexes. The EMBO journal 12, 2799-2808 
(1993). 
36 Barak, Y., Juven, T., Haffner, R. & Oren, M. mdm2 expression is induced 
by wild type p53 activity. The EMBO journal 12, 461-468 (1993). 
37 Wu, X., Bayle, J. H., Olson, D. & Levine, A. J. The p53-mdm-2 
autoregulatory feedback loop. Genes Dev 7, 1126-1132 (1993). 
38 Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid 
degradation of p53. Nature 387, 296-299, doi:10.1038/387296a0 (1997). 
	  	   120 
39 Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin 
ligase E3 for tumor suppressor p53. FEBS Lett 420, 25-27 (1997). 
40 Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. 
The mdm-2 oncogene product forms a complex with the p53 protein and 
inhibits p53-mediated transactivation. Cell 69, 1237-1245 (1992). 
41 Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., 
Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y. & Ziv, Y. Enhanced 
phosphorylation of p53 by ATM in response to DNA damage. Science 
281, 1674-1677 (1998). 
42 Shieh, S. Y., Ikeda, M., Taya, Y. & Prives, C. DNA damage-induced 
phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334 
(1997). 
43 Meek, D. W. & Anderson, C. W. Posttranslational modification of p53: 
cooperative integrators of function. Cold Spring Harb Perspect Biol 1, 
a000950, doi:10.1101/cshperspect.a000950 (2009). 
44 Wang, S. & El-Deiry, W. S. p73 or p53 directly regulates human p53 
transcription to maintain cell cycle checkpoints. Cancer Res 66, 6982-
6989, doi:10.1158/0008-5472.CAN-06-0511 (2006). 
45 Oren, M. Regulation of the p53 tumor suppressor protein. J Biol Chem 
274, 36031-36034 (1999). 
	  	   121 
46 Levine, A. J. & Oren, M. The first 30 years of p53: growing ever more 
complex. Nat Rev Cancer 9, 749-758, doi:10.1038/nrc2723 (2009). 
47 Unger, T., Mietz, J. A., Scheffner, M., Yee, C. L. & Howley, P. M. 
Functional domains of wild-type and mutant p53 proteins involved in 
transcriptional regulation, transdominant inhibition, and transformation 
suppression. Mol Cell Biol 13, 5186-5194 (1993). 
48 Pavletich, N. P., Chambers, K. A. & Pabo, C. O. The DNA-binding 
domain of p53 contains the four conserved regions and the major 
mutation hot spots. Genes Dev 7, 2556-2564 (1993). 
49 Raycroft, L., Wu, H. Y. & Lozano, G. Transcriptional activation by wild-
type but not transforming mutants of the p53 anti-oncogene. Science 
249, 1049-1051 (1990). 
50 Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R. & Prives, C. 
Wild-type p53 activates transcription in vitro. Nature 358, 83-86, 
doi:10.1038/358083a0 (1992). 
51 Walerych, D., Lisek, K. & Del Sal, G. Mutant p53: One, No One, and One 
Hundred Thousand. Front Oncol 5, 289, doi:10.3389/fonc.2015.00289 
(2015). 
	  	   122 
52 Bieging, K. T., Mello, S. S. & Attardi, L. D. Unravelling mechanisms of 
p53-mediated tumour suppression. Nat Rev Cancer 14, 359-370, 
doi:10.1038/nrc3711 (2014). 
53 Chene, P. The role of tetramerization in p53 function. Oncogene 20, 
2611-2617, doi:10.1038/sj.onc.1204373 (2001). 
54 Rodriguez, M. S., Desterro, J. M., Lain, S., Lane, D. P. & Hay, R. T. 
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-
mediated degradation. Mol Cell Biol 20, 8458-8467 (2000). 
55 Iwakuma, T. & Lozano, G. Crippling p53 activities via knock-in mutations 
in mouse models. Oncogene 26, 2177-2184, doi:10.1038/sj.onc.1210278 
(2007). 
56 Shahar, O. D., Gabizon, R., Feine, O., Alhadeff, R., Ganoth, A., Argaman, 
L., Shimshoni, E., Friedler, A. & Goldberg, M. Acetylation of lysine 382 
and phosphorylation of serine 392 in p53 modulate the interaction 
between p53 and MDC1 in vitro. PLoS One 8, e78472, 
doi:10.1371/journal.pone.0078472 (2013). 
57 Tong, Q., Mazur, S. J., Rincon-Arano, H., Rothbart, S. B., Kuznetsov, D. 
M., Cui, G., Liu, W. H., Gete, Y., Klein, B. J., Jenkins, L., Mer, G., 
Kutateladze, A. G., Strahl, B. D., Groudine, M., Appella, E. & Kutateladze, 
	  	   123 
T. G. An acetyl-methyl switch drives a conformational change in p53. 
Structure 23, 322-331, doi:10.1016/j.str.2014.12.010 (2015). 
58 Li, S. S. Specificity and versatility of SH3 and other proline-recognition 
domains: structural basis and implications for cellular signal transduction. 
Biochem J 390, 641-653, doi:10.1042/BJ20050411 (2005). 
59 Pawson, T. & Scott, J. D. Signaling through scaffold, anchoring, and 
adaptor proteins. Science 278, 2075-2080 (1997). 
60 Walker, K. K. & Levine, A. J. Identification of a novel p53 functional 
domain that is necessary for efficient growth suppression. Proc Natl Acad 
Sci U S A 93, 15335-15340 (1996). 
61 Venot, C., Maratrat, M., Dureuil, C., Conseiller, E., Bracco, L. & 
Debussche, L. The requirement for the p53 proline-rich functional 
domain for mediation of apoptosis is correlated with specific PIG3 gene 
transactivation and with transcriptional repression. The EMBO journal 17, 
4668-4679, doi:10.1093/emboj/17.16.4668 (1998). 
62 Zhu, J., Jiang, J., Zhou, W., Zhu, K. & Chen, X. Differential regulation of 
cellular target genes by p53 devoid of the PXXP motifs with impaired 
apoptotic activity. Oncogene 18, 2149-2155, doi:10.1038/sj.onc.1202533 
(1999). 
	  	   124 
63 Sakamuro, D., Sabbatini, P., White, E. & Prendergast, G. C. The 
polyproline region of p53 is required to activate apoptosis but not 
growth arrest. Oncogene 15, 887-898, doi:10.1038/sj.onc.1201263 
(1997). 
64 Berger, M., Vogt Sionov, R., Levine, A. J. & Haupt, Y. A role for the 
polyproline domain of p53 in its regulation by Mdm2. J Biol Chem 276, 
3785-3790, doi:10.1074/jbc.M008879200 (2001). 
65 Baptiste, N., Friedlander, P., Chen, X. & Prives, C. The proline-rich 
domain of p53 is required for cooperation with anti-neoplastic agents to 
promote apoptosis of tumor cells. Oncogene 21, 9-21, 
doi:10.1038/sj.onc.1205015 (2002). 
66 Harlow, E., Williamson, N. M., Ralston, R., Helfman, D. M. & Adams, T. E. 
Molecular cloning and in vitro expression of a cDNA clone for human 
cellular tumor antigen p53. Mol Cell Biol 5, 1601-1610 (1985). 
67 Matlashewski, G. J., Tuck, S., Pim, D., Lamb, P., Schneider, J. & 
Crawford, L. V. Primary structure polymorphism at amino acid residue 72 
of human p53. Mol Cell Biol 7, 961-963 (1987). 
68 Matlashewski, G., Banks, L., Pim, D. & Crawford, L. Analysis of human 
p53 proteins and mRNA levels in normal and transformed cells. Eur J 
Biochem 154, 665-672 (1986). 
	  	   125 
69 Thomas, R., Kaplan, L., Reich, N., Lane, D. P. & Levine, A. J. 
Characterization of human p53 antigens employing primate specific 
monoclonal antibodies. Virology 131, 502-517 (1983). 
70 Matlashewski, G., Lamb, P., Pim, D., Peacock, J., Crawford, L. & 
Benchimol, S. Isolation and characterization of a human p53 cDNA clone: 
expression of the human p53 gene. The EMBO journal 3, 3257-3262 
(1984). 
71 Ara, S., Lee, P. S., Hansen, M. F. & Saya, H. Codon 72 polymorphism of 
the TP53 gene. Nucleic Acids Res 18, 4961 (1990). 
72 Beckman, G., Birgander, R., Sjalander, A., Saha, N., Holmberg, P. A., 
Kivela, A. & Beckman, L. Is p53 polymorphism maintained by natural 
selection? Human heredity 44, 266-270 (1994). 
73 Chimpanzee, S. & Analysis, C. Initial sequence of the chimpanzee 
genome and comparison with the human genome. Nature 437, 69-87, 
doi:10.1038/nature04072 (2005). 
74 Whibley, C., Pharoah, P. D. & Hollstein, M. p53 polymorphisms: cancer 
implications. Nat Rev Cancer 9, 95-107, doi:10.1038/nrc2584 (2009). 
75 Olschwang, S., Laurent-Puig, P., Vassal, A., Salmon, R. J. & Thomas, G. 
Characterization of a frequent polymorphism in the coding sequence of 
	  	   126 
the Tp53 gene in colonic cancer patients and a control population. Hum 
Genet 86, 369-370 (1991). 
76 Zhang, W., Hu, G. & Deisseroth, A. Polymorphism at codon 72 of the p53 
gene in human acute myelogenous leukemia. Gene 117, 271-275 (1992). 
77 Weston, A., Caporaso, N. E., Perrin, L. S., Sugimura, H., Tamai, S., 
Krontiris, T. G., Trump, B. F., Hoover, R. N. & Harris, C. C. Relationship of 
H-ras-1, L-myc, and p53 polymorphisms with lung cancer risk and 
prognosis. Environ Health Perspect 98, 61-67 (1992). 
78 Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J. & Hayashi, S. Germ line 
polymorphisms of p53 and CYP1A1 genes involved in human lung 
cancer. Carcinogenesis 14, 1085-1089 (1993). 
79 Birgander, R., Sjalander, A., Rannug, A., Alexandrie, A. K., Sundberg, M. 
I., Seidegard, J., Tornling, G., Beckman, G. & Beckman, L. P53 
polymorphisms and haplotypes in lung cancer. Carcinogenesis 16, 2233-
2236 (1995). 
80 Weston, A., Perrin, L. S., Forrester, K., Hoover, R. N., Trump, B. F., Harris, 
C. C. & Caporaso, N. E. Allelic frequency of a p53 polymorphism in 
human lung cancer. Cancer Epidemiol Biomarkers Prev 1, 481-483 
(1992). 
	  	   127 
81 Jin, X., Wu, X., Roth, J. A., Amos, C. I., King, T. M., Branch, C., Honn, S. 
E. & Spitz, M. R. Higher lung cancer risk for younger African-Americans 
with the Pro/Pro p53 genotype. Carcinogenesis 16, 2205-2208 (1995). 
82 Murata, M., Tagawa, M., Kimura, M., Kimura, H., Watanabe, S. & Saisho, 
H. Analysis of a germ line polymorphism of the p53 gene in lung cancer 
patients; discrete results with smoking history. Carcinogenesis 17, 261-
264 (1996). 
83 Wu, W. J., Kakehi, Y., Habuchi, T., Kinoshita, H., Ogawa, O., Terachi, T., 
Huang, C. H., Chiang, C. P. & Yoshida, O. Allelic frequency of p53 gene 
codon 72 polymorphism in urologic cancers. Jpn J Cancer Res 86, 730-
736 (1995). 
84 Sjalander, A., Birgander, R., Hallmans, G., Cajander, S., Lenner, P., Athlin, 
L., Beckman, G. & Beckman, L. p53 polymorphisms and haplotypes in 
breast cancer. Carcinogenesis 17, 1313-1316 (1996). 
85 Yung, W. C., Ng, M. H., Sham, J. S. & Choy, D. T. p53 codon 72 
polymorphism in nasopharyngeal carcinoma. Cancer Genet Cytogenet 
93, 181-182 (1997). 
86 Buller, R. E., Sood, A., Fullenkamp, C., Sorosky, J., Powills, K. & 
Anderson, B. The influence of the p53 codon 72 polymorphism on 
	  	   128 
ovarian carcinogenesis and prognosis. Cancer Gene Ther 4, 239-245 
(1997). 
87 Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, 
F., Breuer, J., Leigh, I. M., Matlashewski, G. & Banks, L. Role of a p53 
polymorphism in the development of human papillomavirus-associated 
cancer. Nature 393, 229-234, doi:10.1038/30400 (1998). 
88 Malcolm, E. K., Baber, G. B., Boyd, J. C. & Stoler, M. H. Polymorphism at 
codon 72 of p53 is not associated with cervical cancer risk. Mod Pathol 
13, 373-378, doi:10.1038/modpathol.3880061 (2000). 
89 Klug, S. J., Ressing, M., Koenig, J., Abba, M. C., Agorastos, T., Brenna, S. 
M., Ciotti, M., Das, B. R., Del Mistro, A., Dybikowska, A., Giuliano, A. R., 
Gudleviciene, Z., Gyllensten, U., Haws, A. L., Helland, A., Herrington, C. 
S., Hildesheim, A., Humbey, O., Jee, S. H., Kim, J. W., Madeleine, M. M., 
Menczer, J., Ngan, H. Y., Nishikawa, A., Niwa, Y., Pegoraro, R., Pillai, M. 
R., Ranzani, G., Rezza, G., Rosenthal, A. N., Roychoudhury, S., Saranath, 
D., Schmitt, V. M., Sengupta, S., Settheetham-Ishida, W., Shirasawa, H., 
Snijders, P. J., Stoler, M. H., Suarez-Rincon, A. E., Szarka, K., Tachezy, R., 
Ueda, M., van der Zee, A. G., von Knebel Doeberitz, M., Wu, M. T., 
Yamashita, T., Zehbe, I. & Blettner, M. TP53 codon 72 polymorphism and 
	  	   129 
cervical cancer: a pooled analysis of individual data from 49 studies. 
Lancet Oncol 10, 772-784, doi:10.1016/S1470-2045(09)70187-1 (2009). 
90 Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L. & Matlashewski, 
G. Two polymorphic variants of wild-type p53 differ biochemically and 
biologically. Mol Cell Biol 19, 1092-1100 (1999). 
91 Dumont, P., Leu, J. I., Della Pietra, A. C., 3rd, George, D. L. & Murphy, 
M. The codon 72 polymorphic variants of p53 have markedly different 
apoptotic potential. Nat Genet 33, 357-365, doi:10.1038/ng1093 (2003). 
92 Pim, D. & Banks, L. p53 polymorphic variants at codon 72 exert different 
effects on cell cycle progression. Int J Cancer 108, 196-199, 
doi:10.1002/ijc.11548 (2004). 
93 Sullivan, A., Syed, N., Gasco, M., Bergamaschi, D., Trigiante, G., Attard, 
M., Hiller, L., Farrell, P. J., Smith, P., Lu, X. & Crook, T. Polymorphism in 
wild-type p53 modulates response to chemotherapy in vitro and in vivo. 
Oncogene 23, 3328-3337, doi:10.1038/sj.onc.1207428 (2004). 
94 Siddique, M. & Sabapathy, K. Trp53-dependent DNA-repair is affected 
by the codon 72 polymorphism. Oncogene 25, 3489-3500, 
doi:10.1038/sj.onc.1209405 (2006). 
95 Bergamaschi, D., Samuels, Y., Sullivan, A., Zvelebil, M., Breyssens, H., 
Bisso, A., Del Sal, G., Syed, N., Smith, P., Gasco, M., Crook, T. & Lu, X. 
	  	   130 
iASPP preferentially binds p53 proline-rich region and modulates 
apoptotic function of codon 72-polymorphic p53. Nat Genet 38, 1133-
1141, doi:10.1038/ng1879 (2006). 
96 Dahabreh, I. J., Schmid, C. H., Lau, J., Varvarigou, V., Murray, S. & 
Trikalinos, T. A. Genotype misclassification in genetic association studies 
of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of 
studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J 
Epidemiol 177, 1317-1325, doi:10.1093/aje/kws394 (2013). 
97 Francisco, G., Menezes, P. R., Eluf-Neto, J. & Chammas, R. Arg72Pro 
TP53 polymorphism and cancer susceptibility: a comprehensive meta-
analysis of 302 case-control studies. Int J Cancer 129, 920-930, 
doi:10.1002/ijc.25710 (2011). 
98 Ma, Y., Yang, J., Liu, Z., Zhang, P., Yang, Z., Wang, Y. & Qin, H. No 
significant association between the TP53 codon 72 polymorphism and 
breast cancer risk: a meta-analysis of 21 studies involving 24,063 
subjects. Breast Cancer Res Treat 125, 201-205, doi:10.1007/s10549-
010-0920-1 (2011). 
99 Goncalves, M. L., Borja, S. M., Cordeiro, J. A., Saddi, V. A., Ayres, F. M., 
Vilanova-Costa, C. A. & Silva, A. M. Association of the TP53 codon 72 
	  	   131 
polymorphism and breast cancer risk: a meta-analysis. SpringerPlus 3, 
749, doi:10.1186/2193-1801-3-749 (2014). 
100 Wang, X., Wang, Y. Z., Ma, K. W., Chen, X. & Li, W. MDM2 rs2279744 
and TP53 rs1042522 polymorphisms associated with etoposide- and 
cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage 
small-cell lung cancer patients. Oncology research and treatment 37, 
176-180, doi:10.1159/000360785 (2014). 
101 Okishiro, M., Kim, S. J., Tsunashima, R., Nakayama, T., Shimazu, K., 
Shimomura, A., Maruyama, N., Tamaki, Y. & Noguchi, S. MDM2 SNP309 
and TP53 R72P associated with severe and febrile neutropenia in breast 
cancer patients treated with 5-FU/epirubicin/cyclophosphamide. Breast 
Cancer Res Treat 132, 947-953, doi:10.1007/s10549-011-1637-5 (2012). 
102 Xu, Y., Yao, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Lin, B., Lu, Y. & Xie, 
Y. p53 Codon 72 polymorphism predicts the pathologic response to 
neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer 
Res 11, 7328-7333, doi:10.1158/1078-0432.CCR-05-0507 (2005). 
103 Cattelani, S., Ferrari-Amorotti, G., Galavotti, S., Defferrari, R., Tanno, B., 
Cialfi, S., Vergalli, J., Fragliasso, V., Guerzoni, C., Manzotti, G., Soliera, A. 
R., Menin, C., Bertorelle, R., McDowell, H. P., Inserra, A., Belli, M. L., 
Varesio, L., Tweddle, D., Tonini, G. P., Altavista, P., Dominici, C., 
	  	   132 
Raschella, G. & Calabretta, B. The p53 codon 72 Pro/Pro genotype 
identifies poor-prognosis neuroblastoma patients: correlation with 
reduced apoptosis and enhanced senescence by the p53-72P isoform. 
Neoplasia 14, 634-643 (2012). 
104 Abdel Hamid, T. M., El Gammal, M. M., Eibead, G. T., Saber, M. M. & 
Abol Elazm, O. M. Clinical impact of SNP of P53 genes pathway on the 
adult AML patients. Hematology 20, 328-335, 
doi:10.1179/1607845414Y.0000000200 (2015). 
105 Xie, X., Jin, H., Hu, J., Zeng, Y., Zhou, J., Ouyang, S., Yang, W., Hu, B. & 
Wang, H. Association between single nucleotide polymorphisms in the 
p53 pathway and response to radiotherapy in patients with 
nasopharyngeal carcinoma. Oncology reports 31, 223-231, 
doi:10.3892/or.2013.2808 (2014). 
106 Cescon, D. W., Bradbury, P. A., Asomaning, K., Hopkins, J., Zhai, R., 
Zhou, W., Wang, Z., Kulke, M., Su, L., Ma, C., Xu, W., Marshall, A. L., 
Heist, R. S., Wain, J. C., Lynch, T. J., Jr., Christiani, D. C. & Liu, G. p53 
Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal 
cancer prognosis. Clin Cancer Res 15, 3103-3109, doi:10.1158/1078-
0432.CCR-08-3120 (2009). 
	  	   133 
107 Toyama, T., Zhang, Z., Nishio, M., Hamaguchi, M., Kondo, N., Iwase, H., 
Iwata, H., Takahashi, S., Yamashita, H. & Fujii, Y. Association of TP53 
codon 72 polymorphism and the outcome of adjuvant therapy in breast 
cancer patients. Breast Cancer Res 9, R34, doi:10.1186/bcr1682 (2007). 
108 Tommiska, J., Eerola, H., Heinonen, M., Salonen, L., Kaare, M., Tallila, J., 
Ristimaki, A., von Smitten, K., Aittomaki, K., Heikkila, P., Blomqvist, C. & 
Nevanlinna, H. Breast cancer patients with p53 Pro72 homozygous 
genotype have a poorer survival. Clin Cancer Res 11, 5098-5103, 
doi:10.1158/1078-0432.CCR-05-0173 (2005). 
109 Donehower, L. A. & Lozano, G. 20 years studying p53 functions in 
genetically engineered mice. Nat Rev Cancer 9, 831-841, 
doi:10.1038/nrc2731 (2009). 
110 Post, S. M., Quintas-Cardama, A., Pant, V., Iwakuma, T., Hamir, A., 
Jackson, J. G., Maccio, D. R., Bond, G. L., Johnson, D. G., Levine, A. J. & 
Lozano, G. A high-frequency regulatory polymorphism in the p53 
pathway accelerates tumor development. Cancer Cell 18, 220-230, 
doi:10.1016/j.ccr.2010.07.010 (2010). 
111 Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., 
Chakravarti, A., Clark, A. G., Donnelly, P., Eichler, E. E., Flicek, P., 
Gabriel, S. B., Gibbs, R. A., Green, E. D., Hurles, M. E., Knoppers, B. M., 
	  	   134 
Korbel, J. O., Lander, E. S., Lee, C., Lehrach, H., Mardis, E. R., Marth, G. 
T., McVean, G. A., Nickerson, D. A., Schmidt, J. P., Sherry, S. T., Wang, 
J., Wilson, R. K., Gibbs, R. A., Boerwinkle, E., Doddapaneni, H., Han, Y., 
Korchina, V., Kovar, C., Lee, S., Muzny, D., Reid, J. G., Zhu, Y. M., Wang, 
J., Chang, Y. Q., Feng, Q., Fang, X. D., Guo, X. S., Jian, M., Jiang, H., Jin, 
X., Lan, T. M., Li, G. Q., Li, J. X., Li, Y. R., Liu, S. M., Liu, X., Lu, Y., Ma, X. 
D., Tang, M. F., Wang, B., Wang, G. B., Wu, H. L., Wu, R. H., Xu, X., Yin, 
Y., Zhang, D. D., Zhang, W. W., Zhao, J., Zhao, M. R., Zheng, X. L., 
Lander, E. S., Altshuler, D. M., Gabriel, S. B., Gupta, N., Gharani, N., Toji, 
L. H., Gerry, N. P., Resch, A. M., Flicek, P., Barker, J., Clarke, L., Gil, L., 
Hunt, S. E., Kelman, G., Kulesha, E., Leinonen, R., McLaren, W. M., 
Radhakrishnan, R., Roa, A., Smirnov, D., Smith, R. E., Streeter, I., 
Thormann, A., Toneva, I., Vaughan, B., Zheng-Bradley, X., Bentley, D. R., 
Grocock, R., Humphray, S., James, T., Kingsbury, Z., Lehrach, H., 
Sudbrak, R., Albrecht, M. W., Amstislavskiy, V. S., Borodina, T. A., 
Lienhard, M., Mertes, F., Sultan, M., Timmermann, B., Yaspo, M. L., 
Mardis, E. R., Wilson, R. K., Fulton, L., Fulton, R., Sherry, S. T., Ananiev, 
V., Belaia, Z., Beloslyudtsev, D., Bouk, N., Chen, C., Church, D., Cohen, 
R., Cook, C., Garner, J., Hefferon, T., Kimelman, M., Liu, C. L., Lopez, J., 
Meric, P., O'Sullivan, C., Ostapchuk, Y., Phan, L., Ponomarov, S., 
	  	   135 
Schneider, V., Shekhtman, E., Sirotkin, K., Slotta, D., Zhang, H., McVean, 
G. A., Durbin, R. M., Balasubramaniam, S., Burton, J., Danecek, P., 
Keane, T. M., Kolb-Kokocinski, A., McCarthy, S., Stalker, J., Quail, M., 
Schmidt, J. P., Davies, C. J., Gollub, J., Webster, T., Wong, B., Zhan, Y. 
P., Auton, A., Campbell, C. L., Kong, Y., Marcketta, A., Gibbs, R. A., Yu, 
F. L., Antunes, L., Bainbridge, M., Muzny, D., Sabo, A., Huang, Z. Y., 
Wang, J., Coin, L. J. M., Fang, L., Guo, X. S., Jin, X., Li, G. Q., Li, Q. B., Li, 
Y. R., Li, Z. Y., Lin, H. X., Liu, B. H., Luo, R. B., Shao, H. J., Xie, Y. L., Ye, 
C., Yu, C., Zhang, F., Zheng, H. C., Zhu, H. M., Alkan, C., Dal, E., Kahveci, 
F., Marth, G. T., Garrison, E. P., Kural, D., Lee, W. P., Leong, W. F., 
Stromberg, M., Ward, A. N., Wu, J. T., Zhang, M. Y., Daly, M. J., 
DePristo, M. A., Handsaker, R. E., Altshuler, D. M., Banks, E., Bhatia, G., 
del Angel, G., Gabriel, S. B., Genovese, G., Gupta, N., Li, H., Kashin, S., 
Lander, E. S., McCarroll, S. A., Nemesh, J. C., Poplin, R. E., Yoon, S. C., 
Lihm, J., Makarov, V., Clark, A. G., Gottipati, S., Keinan, A., Rodriguez-
Flores, J. L., Korbel, J. O., Rausch, T., Fritz, M. H., Stuetz, A. M., Flicek, 
P., Beal, K., Clarke, L., Datta, A., Herrero, J., McLaren, W. M., Ritchie, G. 
R. S., Smith, R. E., Zerbino, D., Zheng-Bradley, X., Sabeti, P. C., 
Shlyakhter, I., Schaffner, S. F., Vitti, J., Cooper, D. N., Ball, E. V., Stenson, 
P. D., Bentley, D. R., Barnes, B., Bauer, M., Cheetham, R. K., Cox, A., 
	  	   136 
Eberle, M., Humphray, S., Kahn, S., Murray, L., Peden, J., Shaw, R., 
Kenny, E. E., Batzer, M. A., Konkel, M. K., Walker, J. A., MacArthur, D. 
G., Lek, M., Sudbrak, R., Amstislavskiy, V. S., Herwig, R., Mardis, E. R., 
Ding, L., Koboldt, D. C., Larson, D., Ye, K., Gravel, S., Swaroop, A., 
Chew, E., Lappalainen, T., Erlich, Y., Gymrek, M., Willems, T. F., Simpson, 
J. T., Shriver, M. D., Rosenfeld, J. A., Bustamante, C. D., Montgomery, S. 
B., De La Vega, F. M., Byrnes, J. K., Carroll, A. W., DeGorter, M. K., 
Lacroute, P., Maples, B. K., Martin, A. R., Moreno-Estrada, A., 
Shringarpure, S. S., Zakharia, F., Halperin, E., Baran, Y., Lee, C., Cerveira, 
E., Hwang, J., Malhotra, A., Plewczynski, D., Radew, K., Romanovitch, M., 
Zhang, C. S., Hyland, F. C. L., Craig, D. W., Christoforides, A., Homer, N., 
Izatt, T., Kurdoglu, A. A., Sinari, S. A., Squire, K., Sherry, S. T., Xiao, C. L., 
Sebat, J., Antaki, D., Gujral, M., Noor, A., Ye, K., Burchard, E. G., 
Hernandez, R. D., Gignoux, C. R., Haussler, D., Katzman, S. J., Kent, W. 
J., Howie, B., Ruiz-Linares, A., Dermitzakis, E. T., Devine, S. E., Goncalo, 
R. A., Kang, H. M., Kidd, J. M., Blackwell, T., Caron, S., Chen, W., Emery, 
S., Fritsche, L., Fuchsberger, C., Jun, G., Li, B. S., Lyons, R., Scheller, C., 
Sidore, C., Song, S. Y., Sliwerska, E., Taliun, D., Tan, A., Welch, R., Wing, 
M. K., Zhan, X. W., Awadalla, P., Hodgkinson, A., Li, Y., Shi, X. H., 
Quitadamo, A., Lunter, G., McVean, G. A., Marchini, J. L., Myers, S., 
	  	   137 
Churchhouse, C., Delaneau, O., Gupta-Hinch, A., Kretzschmar, W., Iqbal, 
Z., Mathieson, I., Menelaou, A., Rimmer, A., Xifara, D. K., Oleksyk, T. K., 
Fu, Y. X., Liu, X. M., Xiong, M. M., Jorde, L., Witherspoon, D., Xing, J. C., 
Eichler, E. E., Browning, B. L., Browning, S. R., Hormozdiari, F., Sudmant, 
P. H., Khurana, E., Durbin, R. M., Hurles, M. E., Tyler-Smith, C., Albers, C. 
A., Ayub, Q., Balasubramaniam, S., Chen, Y., Colonna, V., Danecek, P., 
Jostins, L., Keane, T. M., McCarthy, S., Walter, K., Xue, Y. L., Gerstein, M. 
B., Abyzov, A., Balasubramanian, S., Chen, J. M., Clarke, D., Fu, Y., 
Harmanci, A. O., Jin, M., Lee, D., Liu, J., Mu, X. J., Zhang, J., Zhang, Y., 
Li, Y. R., Luo, R. B., Zhu, H. M., Alkan, C., Dal, E., Kahveci, F., Marth, G. 
T., Garrison, E. P., Kural, D., Lee, W. P., Ward, A. N., Wu, J. T., Zhang, M. 
Y., McCarroll, S. A., Handsaker, R. E., Altshuler, D. M., Banks, E., Del 
Angel, G., Genovese, G., Hartl, C., Li, H., Kashin, S., Nemesh, J. C., 
Shakir, K., Yoon, S. C., Lihm, J., Makarov, V., Degenhardt, J., Korbel, J. 
O., Fritz, M. H., Meiers, S., Raeder, B., Rausch, T., Stuetz, A. M., Flicek, 
P., Casale, F. P., Clarke, L., Smith, R. E., Stegle, O., Zheng-Bradley, X., 
Bentley, D. R., Barnes, B., Cheetham, R. K., Eberle, M., Humphray, S., 
Kahn, S., Murray, L., Shaw, R., Lameijer, E. W., Batzer, M. A., Konkel, M. 
K., Walker, J. A., Ding, L., Hall, I., Ye, K., Lacroute, P., Lee, C., Cerveira, 
E., Malhotra, A., Hwang, J., Plewczynski, D., Radew, K., Romanovitch, M., 
	  	   138 
Zhang, C. S., Craig, D. W., Homer, N., Church, D., Xiao, C. L., Sebat, J., 
Antaki, D., Bafna, V., Michaelson, J., Ye, K., Devine, S. E., Gardner, E. J., 
Abecasis, G. R., Kidd, J. M., Mills, R. E., Dayama, G., Emery, S., Jun, G., 
Shi, X. H., Quitadamo, A., Lunter, G., McVean, G. A., Chen, K., Fan, X., 
Chong, Z. C., Chen, T. H., Witherspoon, D., Xing, J. C., Eichler, E. E., 
Chaisson, M. J., Hormozdiari, F., Huddleston, J., Malig, M., Nelson, B. J., 
Sudmant, P. H., Parrish, N. F., Khurana, E., Hurles, M. E., Ben B. l. a. c. k. 
b. u. r. n. e. , Lindsay, S. J., Ning, Z. M., Walter, K., Zhang, Y. J., Gerstein, 
M. B., Abyzov, A., Chen, J. M., Clarke, D., Lam, H., Mu, X. J., Sisu, C., 
Zhang, J., Zhang, Y., Gibbs, R. A., Yu, F. L., Bainbridge, M., Challis, D., 
Evani, U. S., Kovar, C., Lu, J., Muzny, D., Nagaswamy, U., Reid, J. G., 
Sabo, A., Yu, J., Guo, X. S., Li, W. S., Li, Y. R., Wu, R. H., Marth, G. T., 
Garrison, E. P., Leong, W. F., Ward, A. N., del Angel, G., DePristo, M. A., 
Gabriel, S. B., Gupta, N., Hartl, C., Poplin, R. E., Clark, A. G., Rodriguez-
Flores, J. L., Flicek, P., Clarke, L., Smith, R. E., Zheng-Bradley, X., 
MacArthur, D. G., Mardis, E. R., Fulton, R., Koboldt, D. C., Gravel, S., 
Bustamante, C. D., Craig, D. W., Christoforides, A., Homer, N., Izatt, T., 
Sherry, S. T., Xiao, C. L., Dermitzakis, E. T., Abecasis, G. R., Kang, H. M., 
McVean, G. A., Gerstein, M. B., Balasubramanian, S., Habegger, L., Yu, 
H. Y., Flicek, P., Clarke, L., Cunningham, F., Dunham, I., Zerbino, D., 
	  	   139 
Zheng-Bradley, X., Lage, K., Jespersen, J. B., Horn, H., Montgomery, S. 
B., DeGorter, M. K., Khurana, E., Tyler-Smith, C., Chen, Y., Colonna, V., 
Xue, Y. L., Gerstein, M. B., Balasubramanian, S., Fu, Y., Kim, D., Auton, 
A., Marcketta, A., Desalle, R., Narechania, A., Sayres, M. A. W., Garrison, 
E. P., Handsaker, R. E., Kashin, S., McCarroll, S. A., Rodriguez-Flores, J. 
L., Flicek, P., Clarke, L., Zheng-Bradley, X., Erlich, Y., Gymrek, M., 
Willems, T. F., Bustamante, C. D., Mendez, F. L., Poznik, G. D., Underhill, 
P. A., Lee, C., Cerveira, E., Malhotra, A., Romanovitch, M., Zhang, C. S., 
Abecasis, G. R., Coin, L., Shao, H. J., Mittelman, D., Tyler-Smith, C., 
Ayub, Q., Banerjee, R., Cerezo, M., Chen, Y., Fitzgerald, T., Louzada, S., 
Massaia, A., McCarthy, S., Ritchie, G. R., Xue, Y. L., Yang, F. T., Gibbs, R. 
A., Kovar, C., Kalra, D., Hale, W., Muzny, D., Reid, J. G., Wang, J., Dan, 
X., Guo, X. S., Li, G. Q., Li, Y. R., Ye, C., Zheng, X. L., Altshuler, D. M., 
Flicek, P., Clarke, L., Zheng-Bradley, X., Bentley, D. R., Cox, A., 
Humphray, S., Kahn, S., Sudbrak, R., Albrecht, M. W., Lienhard, M., 
Larson, D., Craig, D. W., Izatt, T., Kurdoglu, A. A., Sherry, S. T., Xiao, C. 
L., Haussler, D., Abecasis, G. R., McVean, G. A., Durbin, R. M., 
Balasubramaniam, S., Keane, T. M., McCarthy, S., Stalker, J., Chakravarti, 
A., Knoppers, B. M., Abecasis, G. R., Barnes, K. C., Beiswanger, C., 
Burchard, E. G., Bustamante, C. D., Cai, H. Y., Cao, H. Z., Durbin, R. M., 
	  	   140 
Gerry, N. P., Gharani, N., Gibbs, R. A., Gignoux, C. R., Gravel, S., Henn, 
B., Jones, D., Jorde, L., Kaye, J. S., Keinan, A., Kent, A., Kerasidou, A., Li, 
Y. R., Mathias, R., McVean, G. A., Moreno-Estrada, A., Ossorio, P. N., 
Parker, M., Resch, A. M., Rotimi, C. N., Royal, C. D., Sandoval, K., Su, Y. 
Y., Sudbrak, R., Tian, Z. M., Tishkoff, S., Toji, L. H., Tyler-Smith, C., Via, 
M., Wang, Y. H., Yang, H. M., Yang, L., Zhu, J. Y., Bodmer, W., Bedoya, 
G., Ruiz-Linares, A., Cai, Z. M., Gao, Y., Chu, J. Y., Peltonen, L., Garcia-
Montero, A., Orfao, A., Dutil, J., Martinez-Cruzado, J. C., Oleksyk, T. K., 
Barnes, K. C., Mathias, R. A., Hennis, A., Watson, H., McKenzie, C., 
Qadri, F., LaRocque, R., Sabeti, P. C., Zhu, J. Y., Deng, X. Y., Sabeti, P. 
C., Asogun, D., Folarin, O., Happi, C., Omoniwa, O., Stremlau, M., 
Tariyal, R., Jallow, M., Joof, F. S., Corrah, T., Rockett, K., Kwiatkowski, D., 
Kooner, J., Hien, T. T., Dunstan, S. J., Hang, N. T., Fonnie, R., Garry, R., 
Kanneh, L., Moses, L., Sabeti, P. C., Schieffelin, J., Grant, D. S., Gallo, C., 
Poletti, G., Saleheen, D., Rasheed, A., Brook, L. D., Felsenfeld, A., 
McEwen, J. E., Vaydylevich, Y., Green, E. D., Duncanson, A., Dunn, M., 
Schloss, J. A., Wang, J., Yang, H. M., Auton, A., Brooks, L. D., Durbin, R. 
M., Garrison, E. P., Kang, H. M., Korbel, J. O., Marchini, J. L., McCarthy, 
S., McVean, G. A., Abecasis, G. R. & Consortium, G. P. A global 
	  	   141 
reference for human genetic variation. Nature 526, 68-+, 
doi:10.1038/nature15393 (2015). 
112 Zhu, F., Dolle, M. E., Berton, T. R., Kuiper, R. V., Capps, C., Espejo, A., 
McArthur, M. J., Bedford, M. T., van Steeg, H., de Vries, A. & Johnson, 
D. G. Mouse models for the p53 R72P polymorphism mimic human 
phenotypes. Cancer Res 70, 5851-5859, doi:10.1158/0008-5472.CAN-
09-4646 (2010). 
113 Reinbold, M., Luo, J. L., Nedelko, T., Jerchow, B., Murphy, M. E., 
Whibley, C., Wei, Q. & Hollstein, M. Common tumour p53 mutations in 
immortalized cells from Hupki mice heterozygous at codon 72. 
Oncogene 27, 2788-2794, doi:10.1038/sj.onc.1210932 (2008). 
114 Luo, J. L., Yang, Q., Tong, W. M., Hergenhahn, M., Wang, Z. Q. & 
Hollstein, M. Knock-in mice with a chimeric human/murine p53 gene 
develop normally and show wild-type p53 responses to DNA damaging 
agents: a new biomedical research tool. Oncogene 20, 320-328, 
doi:10.1038/sj.onc.1204080 (2001). 
115 Frank, A. K., Leu, J. I., Zhou, Y., Devarajan, K., Nedelko, T., Klein-Szanto, 
A., Hollstein, M. & Murphy, M. E. The codon 72 polymorphism of p53 
regulates interaction with NF-{kappa}B and transactivation of genes 
	  	   142 
involved in immunity and inflammation. Mol Cell Biol 31, 1201-1213, 
doi:10.1128/MCB.01136-10 (2011). 
116 Azzam, G. A., Frank, A. K., Hollstein, M. & Murphy, M. E. Tissue-specific 
apoptotic effects of the p53 codon 72 polymorphism in a mouse model. 
Cell Cycle 10, 1352-1355 (2011). 
117 Sarkar, J., Dominguez, E., Li, G., Kusewitt, D. F. & Johnson, D. G. 
Modeling gene-environment interactions in oral cavity and esophageal 
cancers demonstrates a role for the p53 R72P polymorphism in 
modulating susceptibility. Mol Carcinog 53, 648-658, 
doi:10.1002/mc.22019 (2014). 
118 Roscoe B. Jackson Memorial Laboratory. & Green, E. L. Biology of the 
laboratory mouse. 2d edn,  (Blakiston Division, 1966). 
119 Roderick, T. H. The Response of Twenty-Seven Inbred Strains of Mice to 
Daily Doses of Whole-Body X-Irradiation. Radiat Res 20, 631-639 (1963). 
120 Lindsay, K. J., Coates, P. J., Lorimore, S. A. & Wright, E. G. The genetic 
basis of tissue responses to ionizing radiation. Br J Radiol 80 Spec No 
1, S2-6, doi:10.1259/bjr/60507340 (2007). 
121 Coates, P. J., Lorimore, S. A., Lindsay, K. J. & Wright, E. G. Tissue-
specific p53 responses to ionizing radiation and their genetic 
	  	   143 
modification: the key to tissue-specific tumour susceptibility? J Pathol 
201, 377-388, doi:10.1002/path.1456 (2003). 
122 Wallace, M., Coates, P. J., Wright, E. G. & Ball, K. L. Differential post-
translational modification of the tumour suppressor proteins Rb and p53 
modulate the rates of radiation-induced apoptosis in vivo. Oncogene 20, 
3597-3608, doi:10.1038/sj.onc.1204496 (2001). 
123 Wakeland, E., Morel, L., Achey, K., Yui, M. & Longmate, J. Speed 
congenics: a classic technique in the fast lane (relatively speaking). 
Immunol Today 18, 472-477 (1997). 
124 Tommiska, J., Eerola, H., Heinonen, M., Salonen, L., Kaare, M., Tallila, J., 
Ristimaki, A., von Smitten, K., Aittomaki, K., Heikkila, P., Blomqvist, C. & 
Nevanlinna, H. Breast cancer patients with p53 Pro72 homozygous 
genotype have a poorer survival. Clin Cancer Res 11, 5098-5103, 
doi:10.1158/1078-0432.CCR-05-0173 (2005). 
125 Bergamaschi, D., Samuels, Y., Sullivan, A., Zvelebil, M., Breyssens, H., 
Bisso, A., Del Sal, G., Syed, N., Smith, P., Gasco, M., Crook, T. & Lu, X. 
iASPP preferentially binds p53 proline-rich region and modulates 
apoptotic function of codon 72-polymorphic p53. Nat Genet 38, 1133-
1141, doi:10.1038/ng1879 (2006). 
	  	   144 
126 Sauter, K. A., Wood, L. J., Wong, J., Iordanov, M. & Magun, B. E. 
Doxorubicin and daunorubicin induce processing and release of 
interleukin-1beta through activation of the NLRP3 inflammasome. Cancer 
Biol Ther 11, 1008-1016 (2011). 
127 Krysko, D. V., Kaczmarek, A., Krysko, O., Heyndrickx, L., Woznicki, J., 
Bogaert, P., Cauwels, A., Takahashi, N., Magez, S., Bachert, C. & 
Vandenabeele, P. TLR-2 and TLR-9 are sensors of apoptosis in a mouse 
model of doxorubicin-induced acute inflammation. Cell Death Differ 18, 
1316-1325, doi:10.1038/cdd.2011.4 (2011). 
128 Tacar, O., Sriamornsak, P. & Dass, C. R. Doxorubicin: an update on 
anticancer molecular action, toxicity and novel drug delivery systems. J 
Pharm Pharmacol 65, 157-170, doi:10.1111/j.2042-7158.2012.01567.x 
(2013). 
129 Rottenberg, S., Nygren, A. O., Pajic, M., van Leeuwen, F. W., van der 
Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., 
van Tellingen, O., Schouten, J. P., Jonkers, J. & Borst, P. Selective 
induction of chemotherapy resistance of mammary tumors in a 
conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci 
U S A 104, 12117-12122, doi:10.1073/pnas.0702955104 (2007). 
	  	   145 
130 Williams, K. M., Hakim, F. T. & Gress, R. E. T cell immune reconstitution 
following lymphodepletion. Semin Immunol 19, 318-330, 
doi:10.1016/j.smim.2007.10.004 (2007). 
131 Benjamin, R. S., Riggs, C. E., Jr. & Bachur, N. R. Pharmacokinetics and 
metabolism of adriamycin in man. Clin Pharmacol Ther 14, 592-600 
(1973). 
132 Wilkinson, P. M., Israel, M., Pegg, W. J. & Frei, E., 3rd. Comparative 
metabolism and excretion of adriamycin in man, monkey, and rat. Cancer 
Chemother Pharmacol 2, 121-125 (1979). 
133 Blum, R. H. & Carter, S. K. Adriamycin. A new anticancer drug with 
significant clinical activity. Ann Intern Med 80, 249-259 (1974). 
134 Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice 
junctions with RNA-Seq. Bioinformatics 25, 1105-1111, 
doi:10.1093/bioinformatics/btp120 (2009). 
135 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor 
package for differential expression analysis of digital gene expression 
data. Bioinformatics 26, 139-140, doi:10.1093/bioinformatics/btp616 
(2010). 
136 Lee, M. G., Han, J., Jeong, S. I., Her, N. G., Lee, J. H., Ha, T. K., Kang, M. 
J., Ryu, B. K. & Chi, S. G. XAF1 directs apoptotic switch of p53 signaling 
	  	   146 
through activation of HIPK2 and ZNF313. Proc Natl Acad Sci U S A 111, 
15532-15537, doi:10.1073/pnas.1411746111 (2014). 
137 Volkova, M. & Russell, R., 3rd. Anthracycline cardiotoxicity: prevalence, 
pathogenesis and treatment. Curr Cardiol Rev 7, 214-220 (2011). 
138 Maier, P., Hartmann, L., Wenz, F. & Herskind, C. Cellular Pathways in 
Response to Ionizing Radiation and Their Targetability for Tumor 
Radiosensitization. Int J Mol Sci 17, doi:10.3390/ijms17010102 (2015). 
139 Hill-Kayser, C. E., Plastaras, J. P., Tochner, Z. & Glatstein, E. TBI during 
BM and SCT: review of the past, discussion of the present and 
consideration of future directions. Bone Marrow Transplant 46, 475-484, 
doi:10.1038/bmt.2010.280 (2011). 
140 Deek, M. P., Benenati, B., Kim, S., Chen, T., Ahmed, I., Zou, W., Aisner, J. 
& Jabbour, S. K. Thoracic Vertebral Body Irradiation Contributes to 
Acute Hematologic Toxicity During Chemoradiation Therapy for Non-
Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 94, 147-154, 
doi:10.1016/j.ijrobp.2015.09.022 (2016). 
141 Kavanagh, B. D., Pan, C. C., Dawson, L. A., Das, S. K., Li, X. A., Ten 
Haken, R. K. & Miften, M. Radiation dose-volume effects in the stomach 
and small bowel. Int J Radiat Oncol Biol Phys 76, S101-107, 
doi:10.1016/j.ijrobp.2009.05.071 (2010). 
	  	   147 
142 Alsner, J., Andreassen, C. N. & Overgaard, J. Genetic markers for 
prediction of normal tissue toxicity after radiotherapy. Semin Radiat 
Oncol 18, 126-135, doi:10.1016/j.semradonc.2007.10.004 (2008). 
143 Parliament, M. B. & Murray, D. Single nucleotide polymorphisms of DNA 
repair genes as predictors of radioresponse. Semin Radiat Oncol 20, 
232-240, doi:10.1016/j.semradonc.2010.05.003 (2010). 
144 Guo, Z., Shu, Y., Zhou, H., Zhang, W. & Wang, H. Radiogenomics helps 
to achieve personalized therapy by evaluating patient responses to 
radiation treatment. Carcinogenesis 36, 307-317, 
doi:10.1093/carcin/bgv007 (2015). 
145 Chang-Claude, J., Ambrosone, C. B., Lilla, C., Kropp, S., Helmbold, I., 
von Fournier, D., Haase, W., Sautter-Bihl, M. L., Wenz, F., Schmezer, P. & 
Popanda, O. Genetic polymorphisms in DNA repair and damage 
response genes and late normal tissue complications of radiotherapy for 
breast cancer. Br J Cancer 100, 1680-1686, doi:10.1038/sj.bjc.6605036 
(2009). 
146 Tan, X. L., Popanda, O., Ambrosone, C. B., Kropp, S., Helmbold, I., von 
Fournier, D., Haase, W., Sautter-Bihl, M. L., Wenz, F., Schmezer, P. & 
Chang-Claude, J. Association between TP53 and p21 genetic 
polymorphisms and acute side effects of radiotherapy in breast cancer 
	  	   148 
patients. Breast Cancer Res Treat 97, 255-262, doi:10.1007/s10549-005-
9119-2 (2006). 
147 Rao, L., Perez, D. & White, E. Lamin proteolysis facilitates nuclear events 
during apoptosis. J Cell Biol 135, 1441-1455 (1996). 
148 Deffie, A., Wu, H., Reinke, V. & Lozano, G. The tumor suppressor p53 
regulates its own transcription. Mol Cell Biol 13, 3415-3423 (1993). 
149 Sharma, A., Singh, K. & Almasan, A. Histone H2AX phosphorylation: a 
marker for DNA damage. Methods Mol Biol 920, 613-626, 
doi:10.1007/978-1-61779-998-3_40 (2012). 
150 Devoy, A., Bunton-Stasyshyn, R. K. A., Tybulewicz, V. L. J., Smith, A. J. H. 
& Fisher, E. M. C. Genomically humanized mice: technologies and 
promises. Nat Rev Genet 13, 14-20, doi:10.1038/nrg3116 (2012). 
151 Zhang, Y., Picetti, R., Butelman, E. R., Ho, A., Blendy, J. A. & Kreek, M. J. 
Mouse Model of the OPRM1 (A118G) Polymorphism: Differential Heroin 
Self-Administration Behavior Compared with Wild-Type Mice. 
Neuropsychopharmacol 40, 1091-1100, doi:10.1038/npp.2014.286 
(2015). 
152 Chen, Z. Y., Jing, D. Q., Bath, K. G., Ieraci, A., Khan, T., Siao, C. J., 
Herrera, D. G., Toth, M., Yang, C., McEwen, B. S., Hempstead, B. L. & 
Lee, F. S. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-
	  	   149 
related behavior. Science 314, 140-143, doi:10.1126/science.1129663 
(2006). 
153 Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V. & Engert, A. 
Cytokine-release syndrome in patients with B-cell chronic lymphocytic 
leukemia and high lymphocyte counts after treatment with an anti-CD20 
monoclonal antibody (rituximab, IDEC-C2B8). Blood 94, 2217-2224 
(1999). 
154 Lim, L. C., Koh, L. P. & Tan, P. Fatal cytokine release syndrome with 
chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old 
patient with chronic lymphocytic leukemia. J Clin Oncol 17, 1962-1963 
(1999). 
155 Seyfizadeh, N., Seyfizadeh, N., Hasenkamp, J. & Huerta-Yepez, S. A 
molecular perspective on rituximab: A monoclonal antibody for B cell 
non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol 
97, 275-290, doi:10.1016/j.critrevonc.2015.09.001 (2016). 
156 Oeckinghaus, A. & Ghosh, S. The NF-kappaB family of transcription 
factors and its regulation. Cold Spring Harb Perspect Biol 1, a000034, 
doi:10.1101/cshperspect.a000034 (2009). 
	  	   150 
157 Strasser, A., Jost, P. J. & Nagata, S. The many roles of FAS receptor 
signaling in the immune system. Immunity 30, 180-192, 
doi:10.1016/j.immuni.2009.01.001 (2009). 
158 Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, 
M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M. & Krammer, P. 
H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA 
damage by anticancer drugs. J Exp Med 188, 2033-2045 (1998). 
159 Brady, J. L., Harrison, L. C., Goodman, D. J., Cowan, P. J., Hawthorne, W. 
J., O'Connell, P. J., Sutherland, R. M. & Lew, A. M. Preclinical screening 
for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID 
model. Clin Transl Immunology 3, e29, doi:10.1038/cti.2014.28 (2014). 
160 Basu, S., Barnoud, T., Kung, C. P., Reiss, M. & Murphy, M. E. The African-
specific S47 polymorphism of p53 alters chemosensitivity. Cell Cycle, 0, 
doi:10.1080/15384101.2016.1215390 (2016). 
161 Jennis, M., Kung, C. P., Basu, S., Budina-Kolomets, A., Leu, J. I., Khaku, 
S., Scott, J. P., Cai, K. Q., Campbell, M. R., Porter, D. K., Wang, X., Bell, 
D. A., Li, X., Garlick, D. S., Liu, Q., Hollstein, M., George, D. L. & Murphy, 
M. E. An African-specific polymorphism in the TP53 gene impairs p53 
tumor suppressor function in a mouse model. Genes Dev 30, 918-930, 
doi:10.1101/gad.275891.115 (2016). 
	  	   151 
162 Dolgin, E. Using DNA, radiation therapy gets personal. Science 353, 
1348-1349, doi:10.1126/science.353.6306.1348 (2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   152 
Vita: 
Emily Domíguez was born in Seattle, Washington, on August 2, 1973, the 
daughter of Ruth and Marles McDonald. She attended a multitude of 
undergraduate universities, worked in diverse fields of employment, and lived in 
several locations within the United States, and in Urguay and Spain, before 
finishing her undergraduate education. In 2010, she graduated from the 
University of Texas, Pan American (now University of Texas Rio Grande Valley) in 
Edinburg, Texas with a Bachelor of Science in Biology. She entered The 
University of Texas Graduate School of Biomedical Sciences at Houston, Texas 
in September, 2010.  
Permanent address: 
145 Short Street 
Bastrop, TX 78602 
 
 
